Neuroactive steroid preparations and methods of use thereof

Abstract

This specification describes pharmaceutical compositions comprising compound I and pharmaceutically acceptable salts thereof, as well as methods of using them for the treatment of conditions related to NMDA receptor modulation. This specification describes pharmaceutical compositions comprising compound I and methods of using them. This specification also describes the use of pharmaceutical compositions for the manufacture of pharmaceuticals for the treatment of diseases or conditions related to NMDA receptor modulation. Compound I is an NMDA modulator. This specification further describes pharmaceutical compositions comprising compound I for use in the treatment of diseases or conditions related to NMDA receptor modulation.

Description

[Technical Field] 【0001】 References to related applications This application claims priority and benefits of U.S. Provisional Application No. 63 / 463,540, filed on 2 May 2023, the disclosures of which are incorporated herein by reference in their entirety. [Background technology] 【0002】 background NMDA receptors are highly expressed in the central nervous system (CNS) and are involved in excitatory synaptic transmission. Activation of these receptors contributes to synaptic plasticity in some situations and excitotoxicity in others. These receptors bind to the neurotransmitters glutamate and glycine, and then Ca2+ 2+ NMDA receptors are ligand-gated ion channels that allow excitatory neurotransmission and are essential for normal CNS function. NMDA receptors are heteromeric complexes composed of NR1, NR2, and / or NR3 subunits, possessing distinct recognition sites for exogenous and endogenous ligands. These recognition sites include binding sites for glycine, glutamate agonists, and modulators. Positive modulators may have potential clinical applications as cognitive enhancers and as useful therapeutic agents in the treatment of psychiatric disorders with reduced or deficient glutamatergic transmission (e.g., Horak et al., J. Neuroscience, 2004, 24(46), 10318-10325). In contrast, negative modulators may be useful therapeutic agents with potential clinical applications in the treatment of psychiatric disorders with pathologically enhanced glutamatergic transmission (e.g., treatment-resistant depression). There remains a need for drug compositions to treat central nervous system disorders associated with NMDA receptor modulation. [Prior art documents] [Non-patent literature] 【0003】 [Non-Patent Document 1] Horak et al., J. Neuroscience, 2004, 24(46), 10318-10325 [Overview of the Initiative] [Means for solving the problem] 【0004】 Summary of the Invention This specification describes pharmaceutical compositions containing compound I and methods of use thereof. It also describes the use of the pharmaceutical composition in the manufacture of pharmaceuticals for the treatment of diseases or conditions related to NMDA receptor modulation. Compound I is an NMDA modulator. Furthermore, it describes methods of using pharmaceutical compositions containing compound I for the treatment of diseases or conditions related to NMDA receptor modulation. Furthermore, it describes the use of this pharmaceutical composition in the manufacture of pharmaceuticals for the treatment of diseases or conditions related to NMDA receptor modulation. Compound I is an NMDA modulator. Furthermore, it describes pharmaceutical compositions containing compound I for use in the treatment of diseases or conditions related to NMDA receptor modulation. 【0005】 In one aspect, this disclosure provides a pharmaceutical composition comprising the following: a) Compound I: [ka] Compound I; or a pharmaceutically acceptable salt thereof; and b) one or more glycerides, the glycerides comprising about 30% to about 100% by weight of monoglycerides. 【0006】 In some embodiments, the pharmaceutical composition contains compound I. In some embodiments, the pharmaceutical composition contains a pharmaceutically acceptable salt of compound I. In some embodiments, the pharmaceutical composition contains about 0.2% to about 0.4% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.25% to about 0.35% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.3% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.3% by weight of compound I. In some embodiments, the pharmaceutical composition contains about 3 mg / g of compound I. In some embodiments, the pharmaceutical composition contains 3 mg / g of compound I. 【0007】 In some embodiments, one or more glycerides are selected from the group consisting of glyceryl mono / dicaprylorate, glyceryl mono / dicaprylorate, glyceryl monocaprylate type 1, glyceryl monocaprylate type 1, glyceryl monocaprylorate type 1, glyceryl monolinoleate, and combinations thereof. In some embodiments, one or more glycerides are selected from the group consisting of glyceryl monocaprylate, glyceryl monolinoleate, and combinations thereof. In some embodiments, the pharmaceutical composition contains glyceryl monocaprylate. In some embodiments, the pharmaceutical composition contains glyceryl monolinoleate. In some embodiments, the pharmaceutical composition contains glyceryl monocaprylate and glyceryl monolinoleate. 【0008】 In some embodiments, the amount of one or more glycerides is approximately 20% by weight to approximately 80% by weight. In some embodiments, the amount of one or more glycerides is approximately 20% by weight to approximately 60% by weight. 【0009】 In some embodiments, the amount of glyceryl monocaprylate in the composition is about 50% to about 80% by weight. In some embodiments, the amount of glyceryl monocaprylate is about 55% to about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate is about 50% by weight. In some embodiments, the amount of glyceryl monocaprylate is 50% by weight. In some embodiments, the amount of glyceryl monocaprylate is about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate is 60% by weight. In some embodiments, the amount of glyceryl monocaprylate is about 20% to about 30% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 20% by weight. In some embodiments, the amount of glyceryl monolinoleate is 20% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 22.5% by weight. In some embodiments, the amount of glyceryl monolinoleate is 22.5% by weight. 【0010】 In some embodiments, the pharmaceutical composition further comprises stearoyl polyoxyl-32 glyceride. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 5% to about 20% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 10% to about 20% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 20% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 20% by weight. 【0011】 In some embodiments, the pharmaceutical composition further comprises a surfactant. In some embodiments, the amount of surfactant is about 10% to about 25% by weight. In some embodiments, the amount of surfactant is about 10% by weight. In some embodiments, the amount of surfactant is 10% by weight. In some embodiments, the amount of surfactant is about 20% by weight. In some embodiments, the amount of surfactant is 20% by weight. In some embodiments, the surfactant is vitamin E TPGS. 【0012】 In some embodiments, the pharmaceutical composition further comprises an antioxidant. In some embodiments, the amount of antioxidant is about 0.005% by weight to about 0.02% by weight. In some embodiments, the amount of antioxidant is about 0.005% by weight. In some embodiments, the amount of antioxidant is 0.005% by weight. In some embodiments, the amount of antioxidant is about 0.01% by weight. In some embodiments, the amount of antioxidant is 0.01% by weight. In some embodiments, the amount of antioxidant is about 0.02% by weight. In some embodiments, the amount of antioxidant is 0.02% by weight. In some embodiments, the antioxidant is butylated hydroxyanisole (BHA). 【0013】 In some embodiments, the Disclosure provides a pharmaceutical composition comprising: a) about 0.3% w / w of Compound I, b) about 60% w / w of Glyceryl Monocaprylate, c) about 20% w / w of Glyceryl Monolinoleate, d) about 20% w / w of Vitamin E TPGS, and e) about 0.01% w / w of Butyrinated Hydroxyanisole. In some embodiments, the Disclosure provides a pharmaceutical composition comprising: a) about 0.3% w / w of Compound I, b) about 50% w / w of Glyceryl Monocaprylate, c) about 22.5% w / w of Glyceryl Monolinoleate, d) about 20% wt% of Vitamin E TPGS, e) about 7.5% wt% of Stearoyl Polyoxyl-32 Glyceride, and f) about 0.01% wt% of Butyrinated Hydroxyanisole. 【0014】 In some embodiments, the pharmaceutical composition is in oral dosage form. In some embodiments, the pharmaceutical composition is a lipid preparation. In some embodiments, the oral dosage form is a soft gelatin capsule, a hard shell capsule, or an oral liquid preparation. 【0015】 In one respect, this disclosure relates to a) Compound I: [ka] Compound I; or a pharmaceutically acceptable salt thereof; and b) one or more glycerides, the glycerides comprising monoglycerides in a weight ratio of about 30% to about 100%. In some embodiments, the soft gelatin capsule contains compound I. In some embodiments, the soft gelatin capsule contains a pharmaceutically acceptable salt of compound I. In some embodiments, the soft gelatin capsule contains compound I in an amount of about 0.2% to about 0.4% by weight. In some embodiments, the soft gelatin capsule contains compound I in an amount of about 0.25% to about 0.35% by weight. In some embodiments, the soft gelatin capsule contains compound I in an amount of about 0.3% by weight. In some embodiments, the soft gelatin capsule contains compound I in an amount of 0.3% by weight. In some embodiments, the soft gelatin capsule contains compound I in an amount of about 3 mg / g. In some embodiments, the soft gelatin capsule contains compound I in an amount of about 3 mg / g. 【0016】 In some embodiments, one or more glycerides in the soft gelatin capsule are selected from the group consisting of glyceryl mono / dicaprylolate, glyceryl mono / dicaprylolate, glyceryl monocaprylate type 1, glyceryl monocaprylate type 1, glyceryl monocaprylolate type 1, glyceryl monolinoleate, and combinations thereof. In some embodiments, one or more glycerides in the soft gelatin capsule are selected from the group consisting of glyceryl monocaprylate, glyceryl monolinoleate, and combinations thereof. In some embodiments, the soft gelatin capsule contains glyceryl monocaprylate. In some embodiments, the soft gelatin capsule contains glyceryl monolinoleate. In some embodiments, the soft gelatin capsule contains glyceryl monocaprylate and glyceryl monolinoleate. In some embodiments, the amount of one or more glycerides in the soft gelatin capsule is from about 20% by weight to about 80% by weight. In some embodiments, the amount of one or more glycerides in the soft gelatin capsule is about 20% by weight to about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate in the soft gelatin capsule is about 50% by weight to about 80% by weight. In some embodiments, the amount of glyceryl monocaprylate in the soft gelatin capsule is about 55% by weight to about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate in the soft gelatin capsule is about 50% by weight. In some embodiments, the amount of glyceryl monocaprylate in the soft gelatin capsule is 50% by weight. In some embodiments, the amount of glyceryl monocaprylate in the soft gelatin capsule is about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate in the soft gelatin capsule is 60% by weight. In some embodiments, the amount of glyceryl monolinoleate in the soft gelatin capsule is about 20% by weight to about 30% by weight. In some embodiments, the amount of glyceryl monolinoleate in the soft gelatin capsule is approximately 20% by weight.In some embodiments, the amount of glyceryl monolinoleate in the soft gelatin capsule is approximately 22.5% by weight. 【0017】 In some embodiments, the soft gelatin capsules further contain stearoyl polyoxyl-32 glyceride. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride in the soft gelatin capsules is about 5% to about 20% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride in the soft gelatin capsules is about 10% to about 20% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride in the soft gelatin capsules is about 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride in the soft gelatin capsules is 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride in the soft gelatin capsules is about 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride in the soft gelatin capsules is 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride in the soft gelatin capsule is approximately 20% by weight. 【0018】 In some embodiments, the soft gelatin capsules further contain a surfactant. In some embodiments, the amount of surfactant in the soft gelatin capsules is about 10% by weight to about 25% by weight. In some embodiments, the amount of surfactant in the soft gelatin capsules is about 10% by weight. In some embodiments, the amount of surfactant in the soft gelatin capsules is 10% by weight. In some embodiments, the amount of surfactant in the soft gelatin capsules is about 20% by weight. In some embodiments, the amount of surfactant in the soft gelatin capsules is 20% by weight. In some embodiments, the surfactant is vitamin E TPGS. In some embodiments, the soft gelatin capsules further contain an antioxidant. In some embodiments, the amount of antioxidant in the soft gelatin capsules is about 0.005% by weight to about 0.02% by weight. In some embodiments, the amount of antioxidant in the soft gelatin capsules is about 0.005% by weight. In some embodiments, the amount of antioxidant contained in the soft gelatin capsules is 0.005% by weight. In some embodiments, the amount of antioxidant contained in the soft gelatin capsules is about 0.01% by weight. In some embodiments, the amount of antioxidant contained in the soft gelatin capsules is 0.01% by weight. In some embodiments, the amount of antioxidant contained in the soft gelatin capsules is about 0.02% by weight. In some embodiments, the amount of antioxidant in the soft gelatin capsules is 0.02% by weight. In some embodiments, the antioxidant is butylated hydroxyanisole (BHA). 【0019】 In some embodiments, the Disclosure provides a soft gelatin capsule comprising: a) about 0.3% w / w of Compound I, b) about 60% w / w of Glyceryl Monocaprylate, c) about 20% w / w of Glyceryl Monolinoleate, d) about 20% by weight of Vitamin E TPGS, and e) about 0.01% by weight of Butyrinated Hydroxyanisole. In some embodiments, the Disclosure provides a soft gelatin capsule comprising: a) about 0.3% w / w of Compound I, b) about 50% w / w of Glyceryl Monocaprylate, c) about 22.5% w / w of Glyceryl Monolinoleate, d) about 20% by weight of Vitamin E TPGS, e) about 7.5% by weight of Stearoyl Polyoxyl-32 Glyceride, and f) about 0.01% by weight of Butyrinated Hydroxyanisole. 【0020】 In some respects, this disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of compound I. [ka] (Compound I) The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Here, after administration of the pharmaceutical composition to a subject, the pharmaceutical composition provides one or more of the following pharmacokinetic parameters: a) C in the range of approximately 8 to approximately 25 ng / mL max ; b) AUC in the range of approximately 100 to 450 ng·h / mL last ; c) In the range of approximately 100 to 500 ng·h / mL AUC(inf) ; d)t max The duration is in the range of approximately 2 to 8 hours; or e) Approximately 70% to 100% bioavailability. 【0021】 In one embodiment, the present disclosure provides a method for treating Huntington's disease in a subject, which comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition disclosed herein. 【0022】 In one aspect, the present disclosure provides a method for treating cognitive impairment in a subject having Huntington's disease, which comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0023】 In one aspect, this disclosure provides a method for treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. This method involves administering a therapeutically effective amount of the pharmaceutical composition disclosed herein to the subject. 【0024】 In one aspect, this disclosure provides a method for improving executive function in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0025】 In one embodiment, the disclosure provides a method for improving working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0026】 In one embodiment, the disclosure provides a method for improving learning in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0027】 In one embodiment, the present disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0028】 In one embodiment, the Disclosure provides a method for improving cognitive function in a subject having Huntington's disease, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0029】 In one aspect, this disclosure provides a method for delaying cognitive decline in subjects with Huntington's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0030】 In one aspect, this disclosure provides a method for treating Parkinson's disease in a subject, which includes administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0031】 In one aspect, the present disclosure provides a method for treating cognitive impairment in a subject having Parkinson's disease, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0032】 In one aspect, this disclosure provides a method for treating mild cognitive impairment (MCI) associated with Parkinson's disease in a subject, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0033】 In one embodiment, the Disclosure provides a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Parkinson's disease. The method involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0034】 In one embodiment, the present disclosure provides a method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Parkinson's disease. The method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0035】 In one embodiment, the disclosure provides a method for improving learning in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0036】 In one embodiment, the disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0037】 In one embodiment, the Disclosure provides a method for improving cognitive function in a subject having Parkinson's disease, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0038】 In one aspect, the present disclosure provides a method for slowing cognitive decline in a subject having Parkinson's disease, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0039】 In one aspect, the present disclosure provides a method for treating Alzheimer's disease in a subject, which includes administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0040】 In one aspect, the Disclosure provides a method for treating cognitive impairment in a subject having Alzheimer's disease, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0041】 In one aspect, the present disclosure provides a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0042】 In one embodiment, the disclosure provides a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease. The method involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0043】 In one embodiment, the present disclosure provides a method for improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0044】 In one embodiment, the disclosure provides a method for improving learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0045】 In one embodiment, the disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0046】 In one embodiment, the Disclosure provides a method for improving cognitive function in a subject having Alzheimer's disease, which involves administering to the subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0047】 In one aspect, this disclosure provides a method for delaying cognitive decline in subjects with Alzheimer's disease, which involves administering to the subjects a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0048】 In one aspect, the Disclosure provides a method for treating mild cognitive impairment associated with Alzheimer's disease, which involves administering a therapeutically effective amount of the pharmaceutical composition disclosed herein to a subject. 【0049】 In one aspect, the disclosure provides a method for improving executive function in subjects with mild cognitive impairment associated with Alzheimer's disease, which includes administering a therapeutically effective amount of the pharmaceutical composition disclosed herein to the subjects. 【0050】 In one aspect, this disclosure provides a method for improving working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective dose of a drug composition capsule disclosed herein. 【0051】 In one embodiment, the disclosure provides a method for improving learning in subjects with mild cognitive impairment associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0052】 In one embodiment, the Disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective amount of the pharmaceutical composition disclosed herein. 【0053】 In one embodiment, the present disclosure provides a method for treating Huntington's disease in a subject. This method involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0054】 In one aspect, this disclosure provides a method for treating cognitive impairment in a subject having Huntington's disease. This method involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0055】 In one aspect, the present disclosure provides a method for treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject, which includes administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0056】 In one respect, this disclosure provides a method for improving executive function in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. This method involves administering to a subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0057】 In one aspect, the present disclosure provides a method for improving working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease, which includes administering to subjects a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0058】 In one embodiment, the Disclosure provides a method for improving learning ability in a subject having mild cognitive impairment (MCI) associated with Huntington's disease, which comprises administering a therapeutically effective amount of the soft gelatin capsules disclosed herein to the subject. 【0059】 In one embodiment, the disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. The method comprises administering to a subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0060】 In one embodiment, the Disclosure provides a method for improving cognitive function in a subject having Huntington's disease, which involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0061】 In one embodiment, the Disclosure provides a method for delaying cognitive decline in a subject having Huntington's disease, comprising administering to the subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0062】 In one embodiment, the Disclosure provides a method for treating Parkinson's disease in a subject, comprising administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0063】 In one aspect, the Disclosure provides a method for treating cognitive impairment in a subject having Parkinson's disease, which involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0064】 In one embodiment, the Disclosure provides a method for treating mild cognitive impairment (MCI) associated with Parkinson's disease in a subject, comprising administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0065】 In one aspect, this disclosure provides a method for improving executive function in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. This method involves administering to a subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0066】 In one embodiment, the disclosure provides a method for improving working memory in a subject having mild cognitive impairment (MCI) associated with Parkinson's disease. The method comprises administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0067】 In one embodiment, the Disclosure provides a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Parkinson's disease, comprising administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0068】 In one embodiment, the disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. The method comprises administering to a subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0069】 In one embodiment, the Disclosure provides a method for improving cognitive function in a subject having Parkinson's disease, which involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0070】 In one embodiment, the present disclosure provides a method for delaying cognitive decline in a subject having Parkinson's disease. This method involves administering to the subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0071】 In one embodiment, the Disclosure provides a method for treating Alzheimer's disease in a subject, comprising administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0072】 In one aspect, the Disclosure provides a method for treating cognitive impairment in a subject having Alzheimer's disease, which involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0073】 In one embodiment, the Disclosure provides a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject, comprising administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0074】 In one embodiment, the disclosure provides a method for improving executive function in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease. The method involves administering to the subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0075】 In one embodiment, the disclosure provides a method for improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0076】 In one embodiment, the Disclosure provides a method for improving learning in a subject having mild cognitive impairment (MCI) associated with Alzheimer's disease, comprising administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0077】 In one embodiment, the disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0078】 In one embodiment, the Disclosure provides a method for improving cognitive function in a subject having Alzheimer's disease, which involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0079】 In one embodiment, the disclosure provides a method for delaying cognitive decline in a subject having Alzheimer's disease. This involves administering to the subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0080】 In one embodiment, the Disclosure provides a method for treating mild cognitive impairment associated with Alzheimer's disease, comprising administering a therapeutically effective amount of the soft gelatin capsules disclosed herein to a subject. 【0081】 In one aspect, this disclosure provides a method for improving executive function in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective dose of the soft gelatin capsules disclosed herein. 【0082】 In one embodiment, the disclosure provides a method for improving working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. The method comprises administering to a subject a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0083】 In one aspect, this disclosure provides a method for improving learning ability in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to subjects a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0084】 In one aspect, this disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to subjects a therapeutically effective amount of the soft gelatin capsules disclosed herein. 【0085】 In some embodiments, the method includes administering compound I to a subject in a total daily dose of about 0.3 mg to about 1.5 mg. In some embodiments, the method includes administering compound I to a subject in a total daily dose of about 0.6 mg to about 1.5 mg. In some embodiments, the method includes administering compound I to a subject in a total daily dose of about 0.9 mg to about 1.2 mg. In some embodiments, the method includes administering compound I to a subject in a total daily dose of about 1.2 mg. In some embodiments, the method includes administering compound I to a subject in a total daily dose of 1.2 mg. In some embodiments, the method includes administering compound I to a subject in a total daily dose of about 0.9 mg. In some embodiments, the method includes administering compound I to a subject in a total daily dose of 0.9 mg. In some embodiments, the method includes administering compound I to a subject in a total daily dose of about 0.6 mg. In some embodiments, the method involves administering a total daily dose of 0.6 mg of compound I to a subject. In some embodiments, the method involves administering a total daily dose of approximately 0.3 mg of compound I to a subject. In some embodiments, the method involves administering a total daily dose of 0.3 mg of compound I to a subject. 【0086】 In some embodiments, the dosage of compound I is administered to subjects at a frequency of once, twice, three times, or four times a day. 【0087】 In some embodiments, the method includes administering to a subject at least one loading dose and at least one maintenance dose. In some embodiments, the method includes administering to a subject a loading dose daily. In some embodiments, the method includes administering to a subject a loading dose daily for at least 2, 4, 6, 8, or 10 weeks. In some embodiments, the method includes administering to a subject a loading dose daily for at least 2 weeks. In some embodiments, the method includes administering to a subject a loading dose daily for at least 4 weeks. In some embodiments, the method includes administering to a subject a loading dose daily for at least 6 weeks. In some embodiments, the method includes administering to a subject a loading dose daily for at least 8 weeks. In some embodiments, the method includes administering to a subject a loading dose daily for at least 10 weeks. In some embodiments, the loading dose is approximately 1.2 mg / day of compound I. In some embodiments, the loading dose is 1.2 mg / day of compound I. In some embodiments, the maintenance dose is administered daily. In some embodiments, the maintenance dose is approximately 0.9 mg / day of compound I. In some embodiments, the maintenance dose is 0.9 mg of compound I per day. In some embodiments, the maintenance dose is approximately 0.6 mg of compound I per day. In some embodiments, the maintenance dose is 0.6 mg of compound I per day. 【0088】 In some respects, this disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of Huntington's disease in subjects. 【0089】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of cognitive impairment in subjects having Huntington's disease. 【0090】 In some respects, this disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of mild cognitive impairment (MCI) associated with Huntington's disease in subjects. 【0091】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein for use in improving executive function in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0092】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein for use in improving working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0093】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in improving learning ability in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0094】 In some respects, this disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0095】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein for use in improving cognitive function in subjects with Huntington's disease. 【0096】 In one respect, the present disclosure provides pharmaceutical compositions disclosed herein that are used to delay cognitive decline in subjects having Huntington's disease. 【0097】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in the treatment of Parkinson's disease in a subject. 【0098】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in the treatment of cognitive impairment in a subject having Parkinson's disease. 【0099】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in the treatment of mild cognitive impairment (MCI) associated with Parkinson's disease in a subject. 【0100】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in improving executive function in subjects having mild cognitive impairment (MCI) associated with Parkinson's disease. 【0101】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein used to improve working memory in subjects having mild cognitive impairment (MCI) associated with Parkinson's disease. 【0102】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in improving learning ability in subjects having mild cognitive impairment (MCI) associated with Parkinson's disease. 【0103】 In some respects, this disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0104】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein used to improve cognitive function in a subject having Parkinson's disease. 【0105】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein used to slow cognitive decline in a subject having Parkinson's disease. 【0106】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in the treatment of Alzheimer's disease in a subject. 【0107】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in the treatment of cognitive impairment in a subject having Alzheimer's disease. 【0108】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in the treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject. 【0109】 In one embodiment, the disclosure provides a pharmaceutical composition disclosed herein for use in improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0110】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein for use in improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0111】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0112】 In some respects, this disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0113】 In some respects, this disclosure provides pharmaceutical compositions disclosed herein for use in improving cognitive function in subjects with Alzheimer's disease. 【0114】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein that are used to delay cognitive decline in subjects having Alzheimer's disease. 【0115】 In one aspect, this disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of mild dementia associated with Alzheimer's disease. 【0116】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein for use in improving executive function in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0117】 In one embodiment, the present disclosure provides a pharmaceutical composition disclosed herein used to improve working memory in subjects having mild cognitive impairment associated with Alzheimer's disease. 【0118】 In one respect, this disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0119】 In some respects, this disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0120】 In some embodiments, the composition is formulated to administer a total daily dose of compound I from about 0.3 mg to about 1.5 mg. In some embodiments, the composition is formulated to administer a total daily dose of compound I from about 1.2 mg. In some embodiments, the composition is formulated to administer a total daily dose of compound I from 1.2 mg. In some embodiments, the composition is prepared to administer a total daily dose of compound I from about 0.9 mg. In some embodiments, the composition is prepared to administer a total daily dose of compound I from 0.9 mg. In some embodiments, the composition is prepared to administer a total daily dose of compound I from about 0.6 mg. In some embodiments, the composition is prepared to administer a total daily dose of compound I from 0.6 mg. In some embodiments, the composition is prepared to administer a total daily dose of compound I from 0.6 mg. In some embodiments, the composition is prepared to administer a total daily dose of compound I from about 0.3 mg. In some embodiments, the composition is prepared to administer a total daily dose of compound I from 0.3 mg. In some embodiments, the treatment includes the administration of at least one loading dose and at least one maintenance dose. 【0121】 In some embodiments, the treatment includes administering a loading dose daily for at least two, four, six, eight, or ten weeks. 【0122】 In some embodiments, treatment includes administering a loading dose daily for at least two weeks. In some embodiments, treatment includes administering a loading dose daily for at least four weeks. In some embodiments, treatment includes administering a loading dose daily for at least six weeks. In some embodiments, treatment includes administering a loading dose daily for at least eight weeks. In some embodiments, treatment includes administering a loading dose daily for at least ten weeks. In some embodiments, the loading dose is approximately 1.2 mg of compound I per day. In some embodiments, the loading dose is 1.2 mg of compound I per day. In some embodiments, the maintenance dose is approximately 0.9 mg of compound I per day. In some embodiments, the maintenance dose is administered daily. In some embodiments, the maintenance dose is 0.9 mg of compound I per day. In some embodiments, the maintenance dose is approximately 0.6 mg of compound I per day. In some embodiments, the maintenance dose is 0.6 mg of compound I per day. 【0123】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for the treatment of Huntington's disease in subjects. 【0124】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of pharmaceuticals for treating cognitive impairment in subjects with Huntington's disease. 【0125】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for the treatment of mild cognitive impairment (MCI) associated with Huntington's disease in subjects. 【0126】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving executive function in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0127】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0128】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for improving learning in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0129】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0130】 In one embodiment, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a pharmaceutical product for improving the cognitive function of a subject having Huntington's disease. 【0131】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for slowing cognitive decline in subjects with Huntington's disease. 【0132】 In one embodiment, the present disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a pharmaceutical product for the treatment of Parkinson's disease in a subject. 【0133】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a pharmaceutical product for treating cognitive impairment in a subject having Parkinson's disease. 【0134】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for the treatment of mild cognitive impairment (MCI) associated with Parkinson's disease in subjects. 【0135】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving executive function in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0136】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0137】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for improving learning in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0138】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals that improve learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0139】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of a pharmaceutical product for improving the cognitive function of a subject having Parkinson's disease. 【0140】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for slowing cognitive decline in subjects with Parkinson's disease. 【0141】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for the treatment of Alzheimer's disease in subjects. 【0142】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for treating cognitive impairment in subjects with Alzheimer's disease. 【0143】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a pharmaceutical product for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject. 【0144】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0145】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0146】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for improving learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0147】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0148】 In one embodiment, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a pharmaceutical product for improving the cognitive function of a subject having Alzheimer's disease. 【0149】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a pharmaceutical product intended to delay cognitive decline in a subject having Alzheimer's disease. 【0150】 In one embodiment, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a pharmaceutical product for the treatment of mild dementia associated with Alzheimer's disease. 【0151】 In one embodiment, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for improving executive function in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0152】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for improving working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0153】 In one aspect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for improving learning ability in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0154】 In one respect, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals that improve learning ability and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0155】 In some embodiments, the total daily dose of compound I is approximately 0.3 mg to approximately 1.5 mg. In some embodiments, the total daily dose of compound I is approximately 1.2 mg. In some embodiments, the total daily dose of compound I is 1.2 mg. In some embodiments, the total daily dose of compound I is approximately 0.9 mg. In some embodiments, the total daily dose of compound I is 0.9 mg. In some embodiments, the total daily dose of compound I is approximately 0.6 mg. In some embodiments, the total daily dose of compound I is 0.6 mg. In some embodiments, the total daily dose of compound I is approximately 0.3 mg. In some embodiments, the total daily dose of compound I is 0.3 mg. In some embodiments, the treatment includes the administration of at least one loading dose and at least one maintenance dose. In some embodiments, the treatment includes the administration of a loading dose daily for at least 2 weeks, 4 weeks, 6 weeks, 8 weeks, or 10 weeks. In some embodiments, the treatment includes the administration of a loading dose daily for at least 2 weeks. In some embodiments, treatment includes administering a loading dose daily for at least 4 weeks. In some embodiments, treatment includes administering a loading dose daily for at least 6 weeks. In some embodiments, treatment includes administering a loading dose daily for at least 8 weeks. In some embodiments, treatment includes administering a loading dose daily for at least 10 weeks. In some embodiments, the loading dose is approximately 1.2 mg of compound I per day. In some embodiments, the loading dose is 1.2 mg of compound I per day. In some embodiments, the maintenance dose is administered daily. In some embodiments, the maintenance dose is approximately 0.9 mg of compound I per day. In some embodiments, the maintenance dose is 0.9 mg of compound I per day. In some embodiments, the maintenance dose is approximately 0.6 mg of compound I per day. In some embodiments, the maintenance dose is 0.6 mg of compound I per day. 【0156】 In some respects, this disclosure provides dosing regimens for administering a therapeutically effective amount of the pharmaceutical compositions disclosed herein to subjects in need. This includes administering to a subject at least one loading dose and at least one maintenance dose. In some embodiments, the loading dose is administered daily for at least 2, 4, 6, 8, or 10 weeks. In some embodiments, the loading dose is administered daily for at least 2 weeks. In some embodiments, the loading dose is administered daily for at least 4 weeks. In some embodiments, the loading dose is administered daily for at least 6 weeks. In some embodiments, the loading dose is administered daily for at least 8 weeks. In some embodiments, the loading dose is administered daily for at least 10 weeks. In some embodiments, the loading dose is approximately 1.2 mg of compound I per day. In some embodiments, the loading dose is 1.2 mg of compound I per day. In some embodiments, the maintenance dose is approximately 0.9 mg of compound I per day. In some embodiments, the maintenance dose is 0.9 mg of compound I per day. In some embodiments, the maintenance dose is approximately 0.6 mg of compound I per day. In some embodiments, the maintenance dose is 0.6 mg of compound I per day. [Brief explanation of the drawing] 【0157】 [Figure 1A] Figure 1A shows a typical XRPD pattern of morphology A. 【0158】 [Figure 1B] Figure 1B shows typical TGA (top) and DSC (bottom) thermal analysis profiles for morphology A. 【0159】 [Figure 2A] Figure 2A shows a typical XRPD pattern of morphology B. 【0160】 [Figure 2B] Figure 2B shows typical TGA (top) and DSC (bottom) thermal profiles for morphology B. 【0161】 [Figure 3A]Figure 3A shows a typical XRPD pattern of morphology C. 【0162】 [Figure 3B] Figure 3B shows typical TGA (top) and DSC (bottom) thermogram profiles for morphology C. 【0163】 [Figure 4B] Figure 4A shows a typical XRPD pattern of morphology D. 【0164】 [Figure 4B] Figure 4B shows typical TGA (top) and DSC (bottom) thermal profiles for morphology D. 【0165】 [Figure 5A] Figure 5A shows a typical XRPD pattern of morphology E. 【0166】 [Figure 5B] Figure 5B shows typical TGA (top) and DSC (bottom) thermal analysis profiles for morphology E. [Modes for carrying out the invention] 【0167】 Detailed description of the invention General definition The term "as used herein" refers to the entirety of this application. 【0168】 Unless otherwise defined herein, scientific and technical terms used in this application have the meanings generally understood by those skilled in the art to which this disclosure pertains. Generally, the nomenclature used in relation to the compounds, compositions and methods described herein is well known and commonly used in the art. 【0169】 Any embodiment described herein (including different embodiments of this disclosure and those described in different parts of the specification, including embodiments described only in the Examples) can be combined with one or more other embodiments of this disclosure unless expressly excluded or inappropriate. The combination of embodiments is not limited to any particular combination asserted by multiple dependent claims. For example, a claim that depends on another claim can be modified to include one or more limitations contained in any other claim that depends on the same base claim. Where elements are presented in list form (e.g., in Marcash group form), each subgroup of the elements is also disclosed, and any element can be removed from the group. 【0170】 Throughout this specification, variations such as “include” or “include” are understood to mean the inclusion of the described singular element (or component) or group of singular elements (or group of components), but not the exclusion of other singular elements (or components) or groups of singular elements (or group of components). 【0171】 Throughout the specification, where a composition is described as having, including, or encompassing (or a variation thereof) certain components, it is assumed that the composition is essentially composed of, or may be composed of, those components. Similarly, where a method or process is described as having, including, or encompassing certain process steps, it is assumed that the process is essentially composed of, or may be composed of, those process steps. Furthermore, it should be understood that the order of steps or the order in which certain operations are performed is not important, as long as the compositions and methods described herein function. Moreover, two or more steps or operations can be performed simultaneously. 【0172】 As used herein, the term “contains” means “contains, but is not limited to.” “Contains” and “contains, but is not limited to” are used interchangeably. Therefore, these terms are understood to mean including the listed single (or component) or group of units (or components), but not to exclude other singles (or components) or groups of units (or components). 【0173】 In this specification, “approximately” or “about” means within the range of tolerance for a particular value as determined by a person skilled in the art, which depends in part on the limits of the method of measuring or determining the value, i.e., the measuring system. 【0174】 The use of “a,” “an,” “the,” and similar demonstrative pronouns in contexts describing elements (particularly in the following claims) is to be interpreted as encompassing both singular and plural forms, unless otherwise stated herein or unless it is clearly inconsistent with the context. 【0175】 As used herein, the term "or" should be understood to mean "and / or" unless the context clearly indicates otherwise. 【0176】 The descriptions of value ranges in this specification are intended as a concise way of individually referring to each individual value (including endpoints) within the range unless otherwise stated, and each individual value is incorporated into the specification as if it were individually stated herein. All methods described herein can be implemented in any suitable order unless otherwise stated herein or unless it is clearly inconsistent with the context. Any examples or illustrative expressions (e.g., “for example”) provided herein are intended merely to more clearly illustrate embodiments and, unless otherwise stated, do not constitute a limitation on the scope of the claims. No expression in the specification should be construed as indicating that non-claim elements are required. 【0177】 All publications, patents, and published patent applications referenced herein are incorporated herein by special reference. In the event of any conflict, this specification, including specific definitions, shall prevail. Furthermore, any particular embodiment of this disclosure that constitutes prior art may be expressly excluded from one or more claims. Such embodiments may be excluded even if they are not expressly described herein, as they are considered to be well known to those skilled in the art. Any particular embodiment of the disclosure may be excluded from any claim for any reason, whether or not it constitutes prior art. 【0178】 The terms “active ingredient,” “active agent,” and “active substance” refer to compounds administered to a subject, either alone or in combination with one or more pharmaceutically acceptable excipients, for the treatment, prevention, or improvement of one or more symptoms of a condition, disorder, or disease. In this specification, “active ingredient,” “active agent,” and “active substance” may refer to optically active isomers of the compounds described herein. 【0179】 The terms “drug” and “therapeutic agent” refer to a compound or pharmaceutical composition thereof administered to a subject to treat, prevent or improve one or more symptoms of a condition, disorder, or disease. 【0180】 As used herein, the term “polymorph” refers to a crystalline form of a compound having a specific crystalline-packed structure, or a salt, hydrate, or solvate thereof. The term “polymorph” also includes pseudopolymorphs, which are typically different solvates of a substance, and therefore their properties differ from those of one another. Accordingly, each different polymorph and pseudopolymorph disclosed herein is considered herein as a distinct single crystalline form. 【0181】 As used herein, the term “crystalline” refers to a solid-state form consisting of an ordered arrangement of structural units. Different crystalline forms of the same compound, or its salts, hydrates, and solvates, arise from different molecular packing in the solid state, resulting in different crystal symmetries and / or unit cell parameters. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardness, crystal shape, optical and electrical properties, stability, and solubility. See, for example, Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing, Easton Pa., 173 (1990); The United States Pharmacopeia, 23rd ed., 1843-1844 (1995) (incorporated herein by reference). In this specification, the terms “crystalline form,” “single crystal form,” “crystalline solid form,” and “polymorph” are used interchangeably. These terms distinguish crystals with different properties (e.g., different XRPD patterns and / or different DSC scan results). 【0182】 The term “substantially pure” refers to a state in which a particular crystalline solid form of Compound I is free of impurities and / or other solid forms of Compound I in at least a specific weight percentage. Specific weight percentages may be 70%, 75%, 80%, 85%, 90%, 95%, 99%, or any percentage between 70% and 100%. In some embodiments, Compound I may be a substantially pure sample of any of the crystalline solid forms described herein. In some embodiments, Compound I may be substantially pure form A. In some embodiments, Compound I may be substantially pure form B. In some embodiments, Compound I may be substantially pure form D. 【0183】 Crystal forms are typically characterized by X-ray powder diffraction (XRPD). The XRPD pattern of reflections (peaks, usually represented by a 2θ angle) is generally recognized as a characteristic of a particular crystal form. The relative intensity of XRPD peaks can vary depending, among other things, on sample preparation techniques, crystal size distribution, filters, sample fixation procedures, and the specific instrument used. In some cases, depending on the type and settings of the instrument, the XRPD pattern may have more (i.e., new) or fewer (i.e., peaks may disappear). Certain peaks may appear as single, double, triple, quadruple, or multi-line peaks, depending on the type and settings of the instrument, its sensitivity, measurement conditions, and the purity of the crystal form. Furthermore, certain peaks in XRPD may appear symmetrical or asymmetrical (e.g., with shoulders). Additionally, instrument variability and other factors can affect the 2θ value. Experienced technicians who understand these variations can use XRPD and other known physicochemical methods to identify or confirm the features and properties that define a particular crystal morphology. 【0184】 The term "characteristic peaks" in the XRPD pattern of the crystalline form of compound I refers to a specific group of peaks where the 2θ values ​​in the range of 0° to 40° are collectively assigned to only one of the crystalline forms of compound I. 【0185】 The term "amorphous" applied to compounds refers to a state in which a substance lacks long-range order at the molecular level and exhibits physical properties of a solid or liquid depending on the temperature. Typically, such substances do not exhibit characteristic X-ray diffraction patterns and are more formally described as liquids, even if they exhibit solid properties. Heating causes a change from solid to liquid properties, which is characterized by a phase change (typically a type II transition, or "glass transition"). 【0186】 The terms "anhydrous" or "anhydrous" are used interchangeably and, when applied to compounds, refer to a solid state that does not contain structural water or other solvent molecules within the crystal lattice. 【0187】 The term "solvate" refers to a compound or salt thereof as described herein, further comprising a stoichiometric or non-stoichiometric amount of solvent bonded by non-covalent intermolecular forces (e.g., hydrogen bonds). If the solvent is water, the solvate is a hydrate. If the solvent contains ethanol, the compound may be an ethanol solvate. 【0188】 The term “stable” in the polymorphs disclosed herein refers to the stability of the polymorphs to heat and / or humidity. 【0189】 The term "medically acceptable" refers to a material, composition, and / or dosage form that has been approved or is eligible for approval by a federal or state regulatory agency or a corresponding agency in a country other than the United States, or that is listed in the United States Pharmacopeia (USP) or other generally accepted pharmacopoeia and is approved for use in animals, more specifically in humans. The term also refers to a compound, material, composition, and / or dosage form that is suitable, within the bounds of sound medical judgment, for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions, or other problems or complications that do not justify a reasonable benefit / risk ratio. 【0190】 "Medically acceptable salt" means a salt of a compound disclosed herein that is pharmaceutically acceptable and has the desired pharmacological activity of the parent compound. In particular, such salts are nontoxic and may be addition salts of inorganic or organic acids and base addition salts. Specifically, this includes the following salts: (1) Addition salts with inorganic acids (such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.) or organic acids (such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxybenzoic acid Loxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]octo-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfate, gluconic acid, glutamic acid, hydroxynaphthic acid, salicylic acid, stearic acid, muconic acid, and similar substances; Or (2) a salt formed by the substitution of an acidic proton present in the parent compound with a metal ion (e.g., alkali metal ions, alkaline earth ions, or aluminum ions) or by a coordination bond with an organic base such as ethanolamine, diethanolamine, triethanolamine, or N-methylglucamine. Salts further include, for illustrative purposes only, sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium. Also included, if the compound contains a basic functional group, are salts of non-toxic organic or inorganic acids such as chlorides, bromides, tartrates, mesylates, acetates, maleates, and oxalates. The term "pharmaceutically acceptable cation" refers to an acceptable cationic counterion of an acidic functional group. Examples of such cations include sodium, potassium, calcium, magnesium, ammonium, and tetraalkylammonium cations. See, for example, Berge et al., J. Pharm. Sci. (1977) 66(1):1-79. 【0191】 "Biological availability" (%F) refers to the proportion of the administered Compound I that reaches the systemic circulation of the test animals or humans. AUC(0 to infinity) represents the total drug exposure over time. The total exposure of the drug upon intravenous administration (AUC Inf or AUC ∞ ) is usually defined as 100% biological availability (F%). 【0192】 "Oral bioavailability" indicates the extent to which Compound I is absorbed into the systemic circulation when the formulation is administered orally, compared to intravenous injection. 【0193】 "Geometric mean" refers to the mean or median value that indicates the central tendency of a group of numerical values by calculating the product of the numerical values. The calculation formula for the geometric mean is GM = (X1·X2·...·X n ) 1 / n . 【0194】 "Plasma concentration" refers to the concentration of Compound 1 in the plasma component of the subject's blood. It is understood that the plasma concentration of Compound 1 may vary significantly among subjects due to variability in metabolism and / or the potential for interaction with other therapeutic drugs. According to one embodiment disclosed herein, the plasma concentration of Compound 1 may vary from subject to subject. Similarly, values such as the maximum plasma concentration (C max ), the time to reach the maximum plasma concentration (t max ), or the area under the plasma concentration-time curve (AUC ∞ ) may also vary from subject to subject. 【0195】 The term "AUC last " refers to the area under the plasma concentration-time curve from time 0 to t last . 【0196】 The term "t last " refers to the time point of the last measurable concentration. 【0197】 The term "t maxThe term "time to reach maximum concentration" refers to the time it takes to reach the maximum concentration. 【0198】 "C max The term "maximum drug concentration in plasma" refers to the highest concentration of a drug in the plasma. 【0199】 "CL z The term " / F" refers to the apparent clearance, measured after extravascular administration and not corrected for bioavailability. 【0200】 The term “V z " / F" refers to the apparent volume of distribution that has not been corrected for bioavailability. 【0201】 In this specification, “modulate” means to alter the activity of a target by directly or indirectly interacting with it, and includes, but is not limited to, enhancing, inhibiting, limiting, or prolonging the activity of a target. 【0202】 In this specification, “modulator” refers to a compound that alters the activity of a molecule. For example, a modulator can increase or decrease a particular activity intensity of a molecule compared to the activity intensity in the absence of the modulator. In certain embodiments, the modulator is an inhibitor, which reduces the activity intensity of one or more molecules. In certain embodiments, the inhibitor completely inhibits one or more activities of a molecule. In certain embodiments, the modulator is an activator, which increases the magnitude of at least one activity of a molecule. In certain embodiments, the presence of a modulator causes an activity that would not occur in the absence of the modulator. 【0203】 The “subjects” to which the drug is intended to be administered include human subjects (i.e., males or females of any age, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, elderly)) and / or non-human animals, including mammals such as primates (e.g., cynomolgus macaques, rhesus macaques), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is human. In certain embodiments, the subject is a non-human animal. The terms “human,” “patient,” and “subject” are used interchangeably herein. 【0204】 In this specification, the terms "disease," "disorder," and "condition" are used interchangeably. 【0205】 In this specification, the terms “to treat,” “to be treated,” or “treatment” include reversing, reducing, or cessating the symptoms, clinical signs, and underlying pathology of a condition by a method that improves or stabilizes the condition of a subject. In this specification, and as will be well understood by those skilled in the art, “treatment” means an approach to obtain beneficial or desirable outcomes, including clinical outcomes. Beneficial or desirable clinical outcomes include, but are not limited to, relief, improvement, reduction in severity, delay in progression, reduction in disease extent, stabilization of the disease state (i.e., no worsening), delay or stabilization of disease progression, improvement or relief of the disease state, and (partial or complete) remission (whether detectable or not). “Treatment” may also mean an extension of survival compared to the expected survival without treatment. Examples of beneficial clinical outcomes are described herein. 【0206】 In this specification, unless otherwise specified, “preventive,” “preventive,” and its variations refer to an effect that occurs before the subject begins to develop a particular disease, disorder, or condition. 【0207】 Generally, the “effective dose” of a compound refers to an amount sufficient to induce the desired biological response. As those skilled in the art will understand, the effective dose of a compound as herein may vary depending on factors such as the desired biological endpoint, the compound’s pharmacokinetics, the disease being treated, the method of administration, and the subject’s age, weight, health status, and medical condition. Effective doses include therapeutic and prophylactic treatments. 【0208】 The terms "pharmacologically effective dose," "therapeutably effective dose," or "therapeutably effective dosage" refer to the amount sufficient to treat a patient's disease. This includes, for example, bringing about a beneficial and / or desirable change in the health of a patient suffering from a disease, treating, curing, suppressing, or improving a physiological response or condition, or delaying or minimizing one or more symptoms associated with a disease, disorder, or condition. Complete therapeutic effects do not necessarily occur with a single dose, but may only occur after a series of doses. Therefore, a therapeutically effective dose may be administered in a single or multiple doses. The exact effective dose required by a subject depends, for example, the subject's physique, health status, age, the nature and severity of the disease, the chosen treatment or combination of treatments, and the method of administration. Experienced technicians can easily determine the effective dose in specific situations through routine experimentation. The terms "pharmacologically effective dose," "therapeutably effective dose," or "therapeutably effective dosage" also refer to the amount required to improve a patient's clinical symptoms. A therapeutically effective dose of a compound also refers to the amount of a therapeutic agent, alone or in combination with other treatments, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective dose" may include a dose that improves the overall treatment, a dose that reduces or avoids the symptoms or causes of a disease or condition, or a dose that enhances the therapeutic effect of another therapeutic agent. 【0209】 In this specification, unless otherwise specified, “prophylactically effective amount” of a compound means an amount sufficient to prevent or prevent the recurrence of a disease, disorder, condition, or one or more symptoms associated therewith. The prophylactically effective amount of a compound means the amount of a therapeutic agent that, alone or in combination with other agents, produces a prophylactic effect in preventing a disease, disorder, or condition. The term “prophylactically effective amount” may include amounts that improve the overall prophylactic effect or enhance the prophylactic effect of other prophylactic agents. 【0210】 A "loading dose" is an initial high dose administered at the start of treatment, which is then reduced to a lower maintenance dose after the therapeutic concentration is rapidly achieved in the body. 【0211】 In this specification, "maintenance dose" refers to a low dose of the drug administered after the loading dose. 【0212】 In this specification, unless otherwise specified, "pharmacokinetics" can be defined as the study of the absorption, distribution, metabolism, and excretion of drugs in the body. "Pharmacokinetics" can also be defined as a branch of pharmacology that studies the characteristic interactions in the absorption, distribution, metabolism, and excretion of drugs, or the methods by which drugs are taken into the body, move within the body, and are removed from the body. 【0213】 The “administration” or “giving” of a substance, compound, or drug to a subject can be carried out using any of the various methods well known to those skilled in the art. For example, a compound or drug may be administered in the form of a softgel, hard shell, or oral solution. Administration may also be carried out, for example, as a single dose, multiple doses, and / or over one or more long periods. In some embodiments, administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug. For example, in this specification, a physician who instructs a patient to self-administer a drug, or a physician who instructs another person to administer a drug, and / or a physician who provides a patient with a prescription for a drug is administering a drug to the patient. When a method is used as part of a treatment regimen that includes multiple drugs or treatments, this disclosure assumes that those drugs may be administered at the same or different times and via the same or different routes of administration. The appropriate method of administering a substance, compound, or drug to a subject depends, for example, on the subject's age, activity level at the time of administration (active / inactive), presence and degree of cognitive impairment at the time of administration, and the chemical and biological properties of the compound or drug (e.g., solubility, digestibility, bioavailability, stability, toxicity). 【0214】 Pharmaceutical composition Another aspect described is a lipid preparation containing compound I or a pharmaceutically acceptable salt thereof, and its use for the treatment of diseases or disorders related to NMDA receptor modulation. These lipid preparations offer the following advantages: a) equivalent exposure levels in high-fat, low-fat / low-calorie, and fasting / postprandial states; b) low exposure variability; c) increased exposure (AUC) of the drug product compared to tablets in all postprandial states; d) increased exposure (AUC) of the drug product compared to tablets in all postprandial states. Cmax increased すること The lipid formulations disclosed herein enable self-emulsification of the formulation upon exposure to gastrointestinal fluid. This ensures uniform dispersion of compound I and the base, guaranteeing consistent absorption of compound I under various feeding / fasting conditions. 【0215】 Therefore, in one respect, this disclosure provides a pharmaceutical composition comprising compound I: [ka] Compound I; or a pharmaceutically acceptable salt thereof; and one or more glycerides, the glycerides comprising about 30% to about 100% by weight of monoglycerides. 【0216】 The pharmaceutical compositions disclosed herein can be prepared using any form of compound I, including, for example, a free base, a salt thereof, or a crystalline form (e.g., hydrate, anhydrous, or solvate). For clarification, when a pharmaceutical composition disclosed herein is prepared using, for example, the crystalline form of compound I, compound I is dissolved in the formulation so that no crystals of compound I are present in the pharmaceutical composition. Similarly, when a pharmaceutical composition disclosed herein is prepared using a pharmaceutically acceptable salt of compound I, the salt form of compound I is completely dissolved in the pharmaceutical composition. 【0217】 In some embodiments, this disclosure provides a pharmaceutical composition comprising compound I: [ka] Compound I; and one or more glycerides, the glycerides comprising about 30% to about 100% (by weight) of monoglycerides. In some embodiments, the pharmaceutical composition is prepared using compound I. In other embodiments, the pharmaceutical composition is prepared using a pharmaceutically acceptable salt of compound I. Compound I and its chemical synthesis are disclosed in U.S. Patent No. 1,0227,375 and PCT Publication No. WO2014160480, the contents of which are incorporated herein by reference. 【0218】 In some embodiments, the pharmaceutical composition is prepared using a crystalline form of compound I. In some embodiments, the crystalline form of compound I is the anhydrous form. In some embodiments, the crystalline form of compound I is the solvate form. In some embodiments, the crystalline form of compound I is the hydrate form. In some embodiments, the crystalline form of compound I is the monohydrate form. In some embodiments, compound I used in the preparation of the pharmaceutical composition disclosed herein is a crystalline form selected from Form A, Form B, Form C, Form D, and Form E. In some embodiments, the crystalline form is Form A. In some embodiments, the crystalline form is Form B. In some embodiments, the crystalline form is Form C. In some embodiments, the crystalline form is Form D. In some embodiments, the crystalline form is Form E. It is a crystalline form selected from Form D and Form E. In some embodiments, the crystalline form is Form A. In some embodiments, the crystalline form is Form B. In some embodiments, the crystalline form is Form C. In some embodiments, the crystalline form is Form D. In some embodiments, the crystalline form is Form E. The preparation of crystalline forms A, B, C, D, and E is disclosed in WO2023250185 and WO2024015201, which are incorporated herein by reference. 【0219】 A. Crystal form A 【0220】 In some embodiments, the crystalline form of compound I used in the preparation of the pharmaceutical compositions disclosed herein is crystalline form A of compound I. In some embodiments, the anhydrous crystalline form of compound I is form A. In some embodiments, crystalline form A has one or more properties selected from the following group: a) XRPD pattern including peaks at 15.3±0.2, 16.6±0.2, and 17.9±0.2°²; b) The XRPD pattern substantially shown in Figure 1A; c) DSC calorimetry profile including an endothermic peak at approximately 203°C; d) DSC thermogram profile substantially shown in Figure 1B; e) A TGA profile showing a loss of at least approximately 0.04 wt% between approximately 25°C and approximately 190°C; and f) The TGA profile is substantially shown in Figure 1B. 【0221】 In some embodiments, morphology A is characterized by an XRPD pattern including peaks at 15.3±0.2, 16.6±0.2, and 17.9±0.2 degrees 2θ. In some embodiments, morphology A is characterized by an XRPD pattern including peaks at 15.3±0.2, 16.6±0.2, and 17.9±0.2 degrees 2θ, and further includes at least one additional peak selected from 11.3±0.2, 14.5±0.2, 17.7±0.2, and 20.1±0.2 degrees 2θ. In some embodiments, morphology A is characterized by an XRPD pattern including peaks at 14.5±0.2, 15.3±0.2, 16.6±0.2, 17.9±0.2, and 20.1±0.2°². In some embodiments, morphology A is characterized by an XRPD pattern showing degrees 11.3±0.2, 14.5±0.2, 15.3±0.2, 16.6±0.2, 17.7±0.2, 17.9±0.2, and 20.1±0.2. In some embodiments, crystalline morphology A is characterized by an XRPD pattern substantially shown in Figure 1A. 【0222】 In some embodiments, form A is characterized by a thermogravimetric analysis (TGA) thermogram showing that form A loses at least about 0.04 wt% between about 25°C and about 190°C. In some embodiments, form A is characterized by a thermogravimetric analysis (TGA) thermogram showing that it loses about 0.04 wt% between about 25°C and about 190°C. In some embodiments, form A is characterized by a thermogravimetric analysis (TGA) thermogram substantially shown in Figure 1B. 【0223】 In some embodiments, morphology A is characterized by a differential scanning calorimetry (DSC) thermogram, substantially as shown in Figure 1B. In some embodiments, morphology A is characterized by a DSC thermogram including an endothermic peak at approximately 203°C. In some embodiments, morphology A is characterized by a DSC thermogram including a melting endothermic peak at approximately 203°C. 【0224】 In some embodiments, form A substantially contains no other polymorphic forms. In some embodiments, form A is at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, form A has at least 90% polymorphic purity. In some embodiments, form A has at least 92% polymorphic purity. In some embodiments, form A has at least 94% polymorphic purity. In some embodiments, form A has at least 96% polymorphic purity. In some embodiments, form A has at least 98% polymorphic purity. In some embodiments, form A has at least 99% polymorphic purity. 【0225】 B. Crystal form B 【0226】 In some embodiments, the crystalline form of compound I used in the preparation of the pharmaceutical compositions disclosed herein is crystalline form B of compound I. In some embodiments, the anhydrous crystalline form of compound I is form B. In some embodiments, form B has one or more properties selected from the following group: a) XRPD pattern including peaks at 14.4±0.2, 16.8±0.2, and 18.5±0.2°²; b) The XRPD pattern substantially shown in Figure 2A; c) DSC calorimetry profile including an endothermic peak at approximately 204°C; d) DSC thermogram profile substantially shown in Figure 2B; e) A TGA profile showing at least about 0.2 wt% loss between about 70°C and about 150°C; and f) The TGA profile is substantially shown in Figure 2B. 【0227】 In some embodiments, form B is characterized by an X-ray powder diffraction (XRPD) pattern that includes peaks at 2θ values ​​of 14.4±0.2, 16.8±0.2, and 18.5±0.2 degrees. In some embodiments, form B is characterized by an XRPD pattern having peaks at positions of 14.4±0.2, 16.8±0.2, and 18.5±0.2°, and further characterized by having an XRPD pattern that includes 10.9±0.2, 15.4±0.2, and 19.0±0.2°. In some embodiments, form B is characterized by having an XRPD pattern that includes 10.9±0.2, 14.4±0.2, 16.8±0.2, 18.5±0.2, and 19.0±0.2°. In some embodiments, morphology B is characterized by an XRPD pattern including peaks at 10.9±0.2, 14.4±0.2, 15.4±0.2, 16.8±0.2, 18.5±0.2, and 19.0±0.2 degrees. In some embodiments, crystalline morphology B is characterized by an XRPD pattern substantially shown in Figure 2A. 【0228】 In some embodiments, form B is characterized by a thermogravimetric analysis (TGA) thermogram showing a loss of at least about 0.2% by weight between about 70°C and about 150°C. In some embodiments, form B is characterized by a thermogravimetric analysis (TGA) thermogram substantially shown in Figure 2B. 【0229】 In some embodiments, form B is characterized by a differential scanning calorimetry (DSC) thermogram, substantially as shown in Figure 2B. In some embodiments, form B is characterized by a DSC thermogram including an endothermic peak at approximately 204°C. In some embodiments, form B is characterized by a DSC thermogram including a melting endothermic peak at approximately 204°C. 【0230】 In some embodiments, form B is substantially free of other polymorphs. In some embodiments, form B is at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, form B has at least 90% polymorphic purity. In some embodiments, form B has at least 92% polymorphic purity. In some embodiments, form B has at least 94% polymorphic purity. In some embodiments, form B has at least 96% polymorphic purity. In some embodiments, form B has at least 98% polymorphic purity. In some embodiments, form B has at least 99% polymorphic purity. 【0231】 C. Crystal form C 【0232】 In some embodiments, the crystalline form of compound I used in the preparation of the pharmaceutical compositions disclosed herein is crystalline form C of compound I. In some embodiments, the hydrate crystalline form of compound I is form C. In some embodiments, the monohydrate crystalline form of compound I is form C. In some embodiments, form C has one or more properties selected from the following group: a) XRPD pattern including peaks at 12.0±0.2°, 15.1±0.2°, and 21.3±0.2°²; b) The XRPD pattern substantially shown in Figure 3A; c) DSC thermogram profile including an endothermic peak at approximately 204°C; d) DSC thermogram profile including an endothermic peak at approximately 120°C; e) DSC thermogram profile substantially shown in Figure 3B; f) TGA profiles showing at least about 3 wt% loss between approximately 23°C and approximately 125°C; and g) The TGA profile is substantially shown in Figure 3B. 【0233】 In some embodiments, morphology C is characterized by an XRPD pattern with peaks at 2θ values ​​of 12.0±0.2, 15.1±0.2, and 21.3±0.2 degrees. In some embodiments, morphology C is characterized by an XRPD pattern having peaks at 12.0±0.2, 15.1±0.2, and 21.3±0.2 degrees, and further characterized by having an XRPD pattern including 12.9±0.2, 16.3±0.2, 17.5±0.2, 20.1±0.2, and 25.8±0.2 degrees. In some embodiments, morphology C is characterized by 12.0±0.2, 15.1±0.2, 16.3±0.2, 17.5±0.2, 20.1±0.2, 21.3±0.2, and 25.8±0.2 degrees. In some embodiments, morphology C is 12.0 ± 0.2, 12.9 ± 0.2, 15.1 ± 0.2, 16.3 ± 0.2, 17.5 ± 0.2, 20.1 ± 0.2, 21.3 ± 0.2, and 25.8 ± 0.2, 2 degrees. In some embodiments, crystalline morphology C is characterized by the XRPD pattern substantially shown in Figure 3A. 【0234】 In some embodiments, morphology C is characterized by a thermogravimetric analysis (TGA) thermogram showing that morphology C loses at least about 3 wt% between about 23°C and about 125°C. In some embodiments, morphology C is characterized by a thermogravimetric analysis (TGA) thermogram showing that it loses about 3–4 wt% between about 23°C and about 125°C. In some embodiments, morphology C is characterized by a thermogravimetric analysis (TGA) thermogram substantially shown in Figure 3B. 【0235】 In some embodiments, form C is characterized by a differential scanning calorimetry (DSC) thermogram, substantially as shown in Figure 3B. In some embodiments, form C is characterized by a DSC thermogram including an endothermic peak at approximately 204°C. In some embodiments, form C is characterized by a DSC thermogram including an endothermic peak at approximately 120°C. In some embodiments, form C is characterized by a DSC thermogram including endothermic peaks at approximately 120°C and approximately 204°C. In some embodiments, form C is characterized by a DSC thermogram including a dehydration endothermic peak at approximately 120°C. In some embodiments, form C is characterized by a DSC thermogram including a melting endothermic peak at approximately 204°C. 【0236】 In some embodiments, form C is substantially free of other polymorphs. In some embodiments, form C is at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, form C has at least 90% polymorphic purity. In some embodiments, form C has at least 92% polymorphic purity. In some embodiments, form C has at least 94% polymorphic purity. In some embodiments, form C has at least 96% polymorphic purity. In some embodiments, form C has at least 98% polymorphic purity. In some embodiments, form C has at least 99% polymorphic purity. 【0237】 D. Crystal form D 【0238】 In some embodiments, the crystalline form of compound I used in the preparation of the pharmaceutical compositions disclosed herein is crystalline form D of compound I. In some embodiments, the monohydrate crystalline form of compound I is form D. In some embodiments, form D has one or more properties selected from the following group: a) XRPD pattern including peaks at 15.2±0.2, 17.4±0.2, and 17.7±0.2°² b) The XRPD pattern substantially shown in Figure 4A; c) DSC calorimetry profile including an endothermic peak at approximately 204°C; d) DSC thermal analysis profile including an endothermic peak at approximately 127°C; e) DSC thermogram profile substantially shown in Figure 4B; f) A TGA profile showing at least about 14 wt% loss between approximately 60°C and approximately 150°C; and g) The TGA profile substantially shown in Figure 4B. 【0239】 In some embodiments, morphology D is characterized by an X-ray powder diffraction (XRPD) pattern including peaks at 2θ values ​​of 15.2±0.2°, 17.4±0.2°, and 17.7±0.2°. In some embodiments, morphology D is characterized by an XRPD pattern including peaks at 15.2±0.2°, 17.4±0.2°, and 17.7±0.2°, and further characterized by having an XRPD pattern including 9.1±0.2°, 16.4±0.2°, 18.3±0.2°, and 18.9±0.2°. In some embodiments, morphology D is characterized by 15.2±0.2°, 16.4±0.2°, 17.4±0.2°, 17.7±0.2°, 18.3±0.2°, and 18.9±0.2°. In some embodiments, morphology D is characterized by an XRPD pattern having 9.1 ± 0.2, 15.2 ± 0.2, 16.4 ± 0.2, 17.4 ± 0.2, 17.7 ± 0.2, 18.3 ± 0.2, and 18.9 ± 0.2°. In some embodiments, crystalline morphology D is characterized by an XRPD pattern substantially shown in Figure 4A. 【0240】 In some embodiments, morphology D is characterized by a thermogravimetric analysis (TGA) thermogram showing that morphology D loses at least about 14% by weight between about 60°C and about 150°C. In some embodiments, morphology D is characterized by a thermogravimetric analysis (TGA) thermogram showing that it loses about 14–15% by weight between about 60°C and about 150°C. In some embodiments, morphology D is characterized by a thermogravimetric analysis (TGA) thermogram showing that it loses about 14% by weight between about 60°C and about 150°C. In some embodiments, morphology D is characterized by a thermogravimetric analysis (TGA) thermogram substantially shown in Figure 4B. 【0241】 In some embodiments, morphology D is characterized by a differential scanning calorimetry (DSC) thermogram, substantially as shown in Figure 4B. In some embodiments, morphology D is characterized by a DSC thermogram including an endothermic peak at approximately 204°C. In some embodiments, morphology D is characterized by a DSC thermogram including an endothermic peak at approximately 127°C. In some embodiments, morphology D is characterized by a DSC thermogram including endothermic peaks at approximately 127°C and approximately 204°C. In some embodiments, morphology D is characterized by a DSC thermal analysis curve including a desolvation endothermic peak at approximately 127°C. In some embodiments, morphology D is characterized by a DSC thermal analysis curve including a melting endothermic peak at approximately 204°C. 【0242】 In some embodiments, form D is substantially free of other polymorphs. In some embodiments, form D is at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, form D has a polymorphic purity of at least 90%. In some embodiments, form D has a polymorphic purity of at least 92%. In some embodiments, form D has a polymorphic purity of at least 94%. In some embodiments, form D has a polymorphic purity of at least 96%. In some embodiments, form D has a polymorphic purity of at least 98%. In some embodiments, form D has a polymorphic purity of at least 99%. 【0243】 D. Crystal form E 【0244】 In some embodiments, the crystalline form is a n-BuOH solvate. In some embodiments, the crystalline form is crystalline form E characterized by an XRPD pattern comprising peaks at 4.9 ± 0.2, 12.0 ± 0.2, 12.2 ± 0.2, and 17.0 ± 0.2 degrees². In some embodiments, the XRPD pattern of crystalline form E further includes at least one additional peak at a position selected from 8.5 ± 0.2, 14.9 ± 0.2, 15.8 ± 0.2, 18.2 ± 0.2, and 21.4 ± 0.2 degrees². In some embodiments, the crystalline morphology is crystalline morphology E, characterized by the XRPD pattern substantially shown in Figure 5A. 【0245】 In some embodiments, the crystalline morphology E has a TGA thermogram substantially shown in Figure 5B. In some embodiments, the crystalline morphology E has a differential scanning calorimetry (DSC) thermogram substantially shown in Figure 5B. In some embodiments, the thermogram includes an endothermic peak at approximately 203°C. In some embodiments, the DSC thermal analysis curve includes an endothermic peak at approximately 87°C. 【0246】 In some embodiments, form E substantially contains no other polymorphs. In some embodiments, form E is at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, form E has at least 90% polymorphic purity. In some embodiments, form E has at least 92% polymorphic purity. In some embodiments, form D has at least 94% polymorphic purity. In some embodiments, form E has at least 96% polymorphic purity. In some embodiments, form E has at least 98% polymorphic purity. In some embodiments, form E has at least 99% polymorphic purity. 【0247】 In some embodiments, the pharmaceutical composition contains about 0.05% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.15% to about 1.0% (by weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.2% to about 1.0% (by weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.25% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.3% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.35% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.4% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.45% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.5% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.55% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.6% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.65% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.7% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.75% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.8% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof.In some embodiments, the pharmaceutical composition contains about 0.85% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.9% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.95% to about 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.9% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.8% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.7% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.6% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.5% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.3% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.2% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.2% to about 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.25% to about 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.3% to about 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.3% to about 0.35% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.25% to about 0.35% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.25% to about 0.3% by weight of compound I or a pharmaceutically acceptable salt thereof.In some embodiments, the pharmaceutical composition contains about 0.25% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.3% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.35% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 0.05%, about 0.1%, about 0.15%, about 0.2%, about 0.25%, about 0.3%, about 0.35%, about 0.4%, about 0.45%, about 0.5%, about 0.55%, about 0.6%, about 0.65%, about 0.7%, about 0.75%, about 0.8%, about 0.85%, about 0.9%, about 0.95%, and about 1% of compound I or a pharmaceutically acceptable salt thereof. 【0248】 In some embodiments, the pharmaceutical composition contains 0.05% to 1.0% (weight / weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1% to 1.0% (weight / weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.15% to 1.0% (weight ratio) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.2% to 1.0% (weight ratio) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.25% to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.3% to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.35% to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.4% to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.45 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.5 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.55 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.6 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.65 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.7 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.75 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.8 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.85 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.9 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof.In some embodiments, the pharmaceutical composition contains 0.95 to 1.0% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.9% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.8% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.7% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.6% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.5% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.3% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.1 to 0.2% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.2 to 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.25% to 0.4% (by weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.3% to 0.4% (by weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.3% to 0.35% (by weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.25% to 0.35% (by weight) of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.25% to 0.3% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.25% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.3% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.35% by weight of compound I or a pharmaceutically acceptable salt thereof.In some embodiments, the pharmaceutical composition contains 0.4% by weight of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 0.05%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, and 1% of compound I or a pharmaceutically acceptable salt thereof. 【0249】 In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.05% to about 1.0% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.1% to about 1.0% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.15% to about 1.0% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.2% to about 1.0% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.25% to about 1.0% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.35% to about 1.0% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.4% to about 1.0% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.45% to about 1.0% (by weight). In some embodiments, the pharmaceutical composition contains about 0.5% to about 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.55% to about 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.6% to about 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.65% to about 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.7% to about 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.75% to about 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains about 0.8% to about 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains about 0.85% to about 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains about 0.9% to about 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains about 0.95% to about 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.9% by weight of compound I. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.8% by weight of compound I. In some embodiments, the pharmaceutical composition contains about 0.1% to about 0.7% (by weight) of compound I.In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.1% to about 0.6% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.1% to about 0.5% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.1% to about 0.4% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.1% to about 0.3% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.1% to about 0.2% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.2% to about 0.4% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.25% to about 0.4% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.3% to about 0.4% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.3% to about 0.35% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.25% to about 0.35% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.25% to about 0.3% (by weight). In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.25% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.3% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.35% by weight. In some embodiments, the pharmaceutical composition contains compound I in an amount of about 0.4% by weight. In some embodiments, the pharmaceutical composition contains compound I in amounts of approximately 0.05%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, and 1%. 【0250】 In some embodiments, the pharmaceutical composition contains 0.05% to 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains 0.1% to 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains 0.15% to 1.0% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains 0.2 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.25 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.3 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.35 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.4 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.45 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.5 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.55 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.6 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.65 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.7 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.75 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.8 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.85 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.9 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.95 to 1.0% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.1 to 0.9% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.1 to 0.8% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.1 to 0.7% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.1 to 0.6% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.1 to 0.5% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.1 to 0.4% by weight of compound I.In some embodiments, the pharmaceutical composition contains 0.1 to 0.3% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.1 to 0.2% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.2 to 0.4% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.25 to 0.4% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.3 to 0.4% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.3% to 0.35% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains 0.25% to 0.35% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains 0.25% to 0.3% (by weight) of compound I. In some embodiments, the pharmaceutical composition contains 0.25% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.3% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.35% by weight of compound I. In some embodiments, the pharmaceutical composition contains 0.4% by weight of compound I. In some embodiments, the pharmaceutical composition contains compound I in amounts of 0.05%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45%, 0.5%, 0.55%, 0.6%, 0.65%, 0.7%, 0.75%, 0.8%, 0.85%, 0.9%, 0.95%, and 1%. 【0251】 In some embodiments, the drug load corresponds to about 0.05 mg to about 1 mg of compound I or a pharmaceutically acceptable salt thereof per gram of total weight of the pharmaceutical composition. For example, about 0.05 mg / g to about 1 mg / g. 【0252】 In some embodiments, the amount of compound I or its pharmaceutically acceptable salt I in the composition is about 50 μg / g to about 3 mg / g. In some embodiments, the amount of compound I or its pharmaceutically acceptable salt in the composition is about 100 μg / g to about 3 mg / g. In some embodiments, the amount of compound I or its pharmaceutically acceptable salt in the composition is about 150 μg / g to about 3 mg / g. In some embodiments, the amount of compound I or its pharmaceutically acceptable salt in the composition is about 500 μg / g to about 10 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is approximately 50 μg / g, approximately 75 μg / g, approximately 100 μg / g, approximately 110 μg / g, approximately 120 μg / g, approximately 130 μg / g, approximately 140 μg / g, approximately 150 μg / g, approximately 160 μg / g, approximately 170 μg / g, approximately 180 μg / g, approximately 190 μg / g, approximately 200 μg / g, approximately 210 μg / g, approximately 220 μg / g, approximately 240 μg / g, approximately 240 μg / g, approximately 250 μg / g, approximately 260 μg / g, approximately 270 μg / g, approximately 280 μg / g, approximately 290 μg / g, approximately 300 μg / g, and approximately 310 μg / g. , about 320μg / g, about 330μg / g, about 340μg / g, about 350μg / g, about 360μg / g, about 370μg / g, about 380μg / g , about 390μg / g, about 400μg / g, about 410μg / g, about 420μg / g, about 430μg / g, about 440μg / g, about 450μg / g , about 460μg / g, about 470μg / g, about 480μg / g, about 490μg / g, about 500μg / g, about 510μg / g, about 520μg / g , about 530μg / g, about 540μg / g, about 550μg / g, about 560μg / g, about 570μg / g, about 580μg / g, about 590μg / g, Approximately 600 μg / g, approximately 610 μg / g, approximately 620 μg / g, approximately 630 μg / g, approximately 640 μg / g, approximately 650 μg / g, approximately 650 μg / g, approximately 660 μg / g, approximately 670 μg / g, approximately 680 μg / g, approximately 690 μg / g, approximately 700 μg / g, approximately 710 μg / g, approximately 720 μg / g, approximately 730 μg / g, approximately 740 μg / g, approximately 750 μg / g, approximately 760 μg / g, approximately 770μg / g, approximately 780 μg / g, approximately 790 μg / g, approximately 800 μg / g, approximately 810 μg / g, approximately 820 μg / g, approximately 830 μg / g, approximately 840 μg / g, approximately 850 μg / g, approximately 860 μg / g, approximately 870 μg / g, approximately 880 μg / g, approximately 890 μg / g, approximately 900 μg / g, approximately 910 μg / g, approximately 920 μg / g, approximately 930μg / g, approximately 940μg / g, approximately 950μg / g, approximately 950μg / g, approximately 960μg / g, approximately 970μg / g, approximately 980μg / g, approximately 990μg / g, approximately 1mg / g, approximately 1.1mg / g, approximately 1.2mg / g, approximately 1.3mg / g, approximately 1.4mg / g, approximately 1.5mg / g, 1.6mg / g, 1.7 mg / g, 1.8 mg / g, 1.9 mg / g, approximately 2 mg / g, approximately 2.1 mg / g, approximately 2.2 mg / g, approximately 2.3 mg / g, approximately 2.4 mg / g, approximately 2.5 mg / g, approximately 2.6 mg / g, approximately 2.7 mg / g, approximately 2.8 mg / g, approximately 2.9 mg / g, approximately 3 mg / g, 3.1 mg / g, approximately 3.2 mg / g, approximately 3.3 mg / g, approximately 3.4 mg / g, approximately 3.5 mg / g, approximately 3.6 mg / g, approximately 3.7 mg / g, approximately 3.8 mg / g, approximately 3.9 mg / g, approximately 4 mg / g, approximately 4.1 mg / g, approximately 4.2 mg / g, approximately 4.3 mg / g, approximately 4.4 mg / g, approximately 4.5 mg / g, approximately 4.6 mg / g, approximately 4.7 mg / g, approximately 4.8 mg / g. mg / g, approximately 4.9 mg / g, approximately 5 mg / g, approximately 5.1 mg / g, approximately 5.2 mg / g, approximately 5.3 mg / g, approximately 5.4 mg / g, approximately 5.5 mg / g, approximately 5.6 mg / g, approximately 5.7 mg / g, approximately 5.8 mg / g, approximately 5.9 mg / g, approximately 6 mg / g, approximately 6.1 mg / g, approximately 6.2 mg / g, approximately 6.3 mg / g, approximately 6.4 mg / g, approximately 6.5 mg / g, approximately 6.6 mg / g, approximately 6.7 mg / g, approximately 6.8 mg / g, approximately 6.9 mg / g, approximately 7 mg / g, approximately 7.1 mg / g, approximately 7.2 mg / g, approximately 7.3 mg / g, approximately 7.4 mg / g, approximately 7.5 mg / g, approximately 7.6 mg / g, approximately 7.7 mg / g, approximately 7.8 mg / g, approximately 7.9 mg / g. mg / g, approximately 8 mg / g, approximately 8.1 mg / g, approximately 8.2 mg / g, approximately 8.3 mg / g, approximately 8.4 mg / g, approximately 8.5 mg / g, approximately 8.6 mg / g, approximately 8.7 mg / g, approximately 8.8 mg / g, approximately 8.9 mg / g, approximately 9 mg / g, approximately 9.1 mg / gmg / g, approximately 9.2 mg / g, approximately 9.3 mg / g, approximately 9.4 mg / g, approximately 9.5 mg / g, approximately 9.6 mg / g, approximately 9.7 mg / g, approximately 9.8 mg / g, approximately 9.9 mg / g, or approximately 10 mg / g. 【0253】 In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 50 μg / g to 3 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 100 μg / g to 3 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 150 μg / g to 3 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 500 μg / g to 10 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 50 μg / g, 75 μg / g, 100 μg / g, 110 μg / g, 120 μg / g, 130 μg / g, 140 μg / g, 150 μg / g, 160 μg / g, 170 μg / g, 180 μg / g, 190 μg / g, 200 μg / g, 210 μg / g, 220 μg / g, 240 μg / g, 240 μg / g, 250 μg / g, 260 μg / g, 270 μg / g, 280 μg / g, 290 μg / g, 300 μg / g, 310 μg / g, 320 μg / g, 330 μg / g, 340 μg / g, 350 μg / g, 360 μg / g μg / g, 370 μg / g, 380 μg / g, 390 μg / g, 400 μg / g, 410 μg / g, 420 μg / g, 430 μg / g, 440 μg / g, 450 μg / g, 460 μg / g, 470 μg / g, 480 μg / g, 490 μg / g, 500 μg / g, 510 μg / g, 520 μg / g, 530 μg / g, 540 μg / g, 550 μg / g, 560 μg / g, 570 μg / g, 580 μg / g, 590 μg / g, 600 μg / g, 610 μg / g, 620 μg / g, 630 μg / g, 640 μg / g, 650 μg / g, 650 μg / g, 660 μg / g, 670 μg / g, 680 μg / g, 690 μg / g, 700 μg / g, 710 μg / g, 720 μg / g, 730 μg / g, 740 μg / g, 750 μg / g, 760 μg / g, 770 μg / g, 780 μg / g, 790 μg / g, 800 μg / g, 810 μg / g, 820 μg / g, 830 μg / g, 840 μg / g, 850 μg / g, 860 μg / g, 870 μg / g, 880μg / g、890 μg / g、900 μg / g、910 μg / g 920 μg / g 930 μg / g 940 μg / g 950 μg / g, 950 μg / g, 960 μg / g, 970 μg / g, 980 μg / g, 990 μg / g, 1 mg / g、1.1 mg / g、1.2 mg / g、1.3 mg / g、1.4 mg / g、1.5 mg / g、1.6 mg / g、1.7 mg / g、1.8 mg / g、1.9 mg / g、2 mg / g、2.1 mg / g、2.2 mg / g、2.3 mg / g、2.4 mg / g、2.5 mg / g、2.6 mg / g、2.7 mg / g、2.8 mg / g、2.9 mg / g、3 mg / g、3.1 mg / g、3.2 mg / g、3.3 mg / g、3.4 mg / g、3.5 mg / g、3.6 mg / g、3.7 mg / g、3.8 mg / g、3.9 mg / g、4 mg / g、4.1 mg / g、4.2 mg / g、4.3 mg / g、4.4 mg / g、4.5 mg / g、4.6 mg / g、4.7 mg / g、4.8 mg / g、4.9 mg / g、5 mg / g、5.1 mg / g、5.2 mg / g、5.3 mg / g、5.4 mg / g、5.5 mg / g、5.6 mg / g、5.7 mg / g、5.8 mg / g、5.9 mg / g、6 mg / g、6.1 mg / g、6.2 mg / g、6.3 mg / g、6.4 mg / g、6.5 mg / g、6.6 mg / g、6.7 mg / g , 6.8 mg / g, 6.9 mg / g, 7 mg / g, 7.1 mg / g, 7.2 mg / g, 7.3 mg / g, 7.4 mg / g, 7.5 mg / g, 7.6 mg / g, 7.7 mg / g, 7.8 mg / g、7.9 mg / g、8 mg / g、8.1 mg / g、8.2 mg / g、8.3 mg / g、8.4 mg / g、8.5 mg / g、8.6 mg / g、8.7 mg / g、8.8 mg / g、8.9 mg / g、9 mg / g、9.1 mg / g、9.2 mg / g、9.3 mg / g、9.4 mg / g、9.5 mg / g、9.6 mg / g、9.7 mg / g、9.8 mg / g、9.9 mg / g、または10 mg / g。 【0254】 In some embodiments, the amount of compound I in the composition is about 50 μg / g to about 3 mg / g. In some embodiments, the amount of compound I in the composition is about 100 μg / g to about 3 mg / g. In some embodiments, the amount of compound I in the composition is about 150 μg / g to about 3 mg / g. In some embodiments, the amount of compound I in the composition is about 500 μg / g to about 10 mg / g. In some embodiments, the amount of compound I in the composition is approximately 50 μg / g, approximately 75 μg / g, approximately 100 μg / g, approximately 110 μg / g, approximately 120 μg / g, approximately 130 μg / g, approximately 140 μg / g, approximately 150 μg / g, approximately 160 μg / g, approximately 170 μg / g, approximately 180 μg / g, approximately 190 μg / g, approximately 200 μg / g, approximately 210 μg / g, approximately 220 μg / g, approximately 240 μg / g, approximately 240 μg / g, approximately 250 μg / g, approximately 260 μg / g, approximately 270 μg / g, approximately 280 μg / g, approximately 290 μg / g, approximately 300 μg / g, approximately 310 μg / g, and approximately 320 μg / g. g / g, approximately 330μg / g, approximately 340μg / g, approximately 350μg / g, approximately 360μg / g, approximately 370μg / g, approximately 380μg / g, approximately 39 0μg / g, approximately 400μg / g, approximately 410μg / g, approximately 420μg / g, approximately 430μg / g, approximately 440μg / g, approximately 450μg / g, approximately 4 60μg / g, about 470μg / g, about 480μg / g, about 490μg / g, about 500μg / g, about 510μg / g, about 520μg / g, about 530μg / g, approximately 540μg / g, approximately 550μg / g, approximately 560μg / g, approximately 570μg / g, approximately 580μg / g, approximately 590μg / g, Approximately 600 μg / g, approximately 610 μg / g, approximately 620 μg / g, approximately 630 μg / g, approximately 640 μg / g, approximately 650 μg / g, approximately 650 μg / g, approximately 660 μg / g, approximately 670 μg / g, approximately 680 μg / g, approximately 690 μg / g, approximately 700 μg / g, approximately 710 μg / g, approximately 720 μg / g, approximately 730 μg / g, approximately 740 μg / g, approximately 750 μg / g, approximately 760 μg / g, approximately 770μg / g, approximately 780 μg / g, approximately 790 μg / g, approximately 800 μg / g, approximately 810 μg / g, approximately 820 μg / g, approximately 830 μg / g, approximately 840 μg / g, approximately 850 μg / g, approximately 860 μg / g, approximately 870 μg / g, approximately 880 μg / g, approximately 890 μg / g, approximately 900 μg / g, approximately 910 μg / g, approximately 920 μg / g, approximately 930μg / g, approximately 940μg / g, approximately 950μg / g, approximately 950μg / g, approximately 960μg / g, approximately 970μg / g, approximately 980μg / g, approximately 990μg / g, approximately 1mg / g, approximately 1.1mg / g, approximately 1.2mg / g, approximately 1.3mg / g, approximately 1.4mg / g, approximately 1.5mg / g, 1.6mg / g, 1.7 mg / g, 1.8 mg / g, 1.9 mg / g, approximately 2 mg / g, approximately 2.1 mg / g, approximately 2.2 mg / g, approximately 2.3 mg / g, approximately 2.4 mg / g, approximately 2.5 mg / g, approximately 2.6 mg / g, approximately 2.7 mg / g, approximately 2.8 mg / g, approximately 2.9 mg / g, approximately 3 mg / g, 3.1 mg / g, approximately 3.2 mg / g, approximately 3.3 mg / g, approximately 3.4 mg / g, approximately 3.5 mg / g, approximately 3.6 mg / g, approximately 3.7 mg / g, approximately 3.8 mg / g, approximately 3.9 mg / g, approximately 4 mg / g, approximately 4.1 mg / g, approximately 4.2 mg / g, approximately 4.3 mg / g, approximately 4.4 mg / g, approximately 4.5 mg / g, approximately 4.6 mg / g, approximately 4.7 mg / g, approximately 4.8 mg / g. mg / g, approximately 4.9 mg / g, approximately 5 mg / g, approximately 5.1 mg / g, approximately 5.2 mg / g, approximately 5.3 mg / g, approximately 5.4 mg / g, approximately 5.5 mg / g, approximately 5.6 mg / g, approximately 5.7 mg / g, approximately 5.8 mg / g, approximately 5.9 mg / g, approximately 6 mg / g, approximately 6.1 mg / g, approximately 6.2 mg / g, approximately 6.3 mg / g, approximately 6.4 mg / g, approximately 6.5 mg / g, approximately 6.6 mg / g, approximately 6.7 mg / g, approximately 6.8 mg / g, approximately 6.9 mg / g, approximately 7 mg / g, approximately 7.1 mg / g, approximately 7.2 mg / g, approximately 7.3 mg / g, approximately 7.4 mg / g, approximately 7.5 mg / g, approximately 7.6 mg / g, approximately 7.7 mg / g, approximately 7.8 mg / g, approximately 7.9 mg / g. mg / g, approximately 8 mg / g, approximately 8.1 mg / g, approximately 8.2 mg / g, approximately 8.3 mg / g, approximately 8.4 mg / g, approximately 8.5 mg / g, approximately 8.6 mg / g, approximately 8.7 mg / g, approximately 8.8 mg / g, approximately 8.9 mg / g, approximately 9 mg / g, approximately 9.1 mg / gmg / g, approximately 9.2 mg / g, approximately 9.3 mg / g, approximately 9.4 mg / g, approximately 9.5 mg / g, approximately 9.6 mg / g, approximately 9.7 mg / g, approximately 9.8 mg / g, approximately 9.9 mg / g, or approximately 10 mg / g. 【0255】 In some embodiments, the amount of compound I in the composition is 50 μg / g to 3 mg / g. In some embodiments, the amount of compound I in the composition is 100 μg / g to 3 mg / g. In some embodiments, the amount of compound I in the composition is 150 μg / g to 3 mg / g. In some embodiments, the amount of compound I in the composition is 500 μg / g to 10 mg / g. In some embodiments, the amount of Compound I in the composition is 50 μg / g, 75 μg / g, 100 μg / g, 110 μg / g, 120 μg / g, 130 μg / g, 140 μg / g, 150 μg / g, 160 μg / g g, 170μg / g, 180μg / g, 190μg / g, 200μg / g, 210μg / g, 220μg / g, 240μg / g, 240μg / g, 250μg / g, 260μg / g, 270μg / g, 280 μg / g, 290 μg / g, 300 μg / g, 310 μg / g, 320 μg / g, 330 μg / g, 340 μg / g, 350 μg / g, 360 μg / g, 370 μg / g, 380 μg / g, 390 μg / g, 400 μg / g, 410 μg / g, 420 μg / g, 430 μg / g, 440 μg / g, 450 μg / g, 460 μg / g, 470 μg / g, 480 μg / g, 490 μg / g, 500 μg / g, 510 μg / g, 520 μg / g, 530 μg / g, 540 μg / g, 550 μg / g, 560 μg / g, 570 μg / g, 580 μg / g, 590 μg / g, 600 μg / g, 610 μg / g, 620 μg / g, 630 μg / g, 640 μg / g, 650 μg / g, 650 μg / g, 660 μg / g, 670 μg / g, 680 μg / g, 690 μg / g, 700 μg / g, 710 μg / g, 720 μg / g, 730 μg / g, 740 μg / g, 750 μg / g, 760 μg / g, 770 μg / g, 780 μg / g, 790 μg / g, 800 μg / g, 810 μg / g, 820 μg / g, 830 μg / g, 840 μg / g, 850 μg / g, 860 μg / g, 870 μg / g, 880 μg / g, 890 μg / g, 900 μg / g, 910 μg / g 920 μg / g 930 μg / g 940 μg / g 950 μg / g, 950 μg / g,960 μg / g, 970 μg / g, 980 μg / g, 990 μg / g, 1 mg / g、1.1 mg / g、1.2 mg / g、1.3 mg / g、1.4 mg / g、1.5 mg / g、1.6 mg / g、1.7 mg / g、1.8 mg / g、1.9 mg / g、2 mg / g、2.1 mg / g、2.2 mg / g、2.3 mg / g、2.4 mg / g、2.5 mg / g、2.6 mg / g、2.7 mg / g、2.8 mg / g、2.9 mg / g、3 mg / g、3.1 mg / g、3.2 mg / g、3.3 mg / g、3.4 mg / g、3.5 mg / g、3.6 mg / g、3.7 mg / g、3.8 mg / g、3.9 mg / g、4 mg / g、4.1 mg / g、4.2 mg / g、4.3 mg / g、4.4 mg / g、4.5 mg / g、4.6 mg / g、4.7 mg / g、4.8 mg / g、4.9 mg / g、5 mg / g、5.1 mg / g、5.2 mg / g、5.3 mg / g、5.4 mg / g、5.5 mg / g、5.6 mg / g、5.7 mg / g、5.8 mg / g、5.9 mg / g、6 mg / g、6.1 mg / g、6.2 mg / g、6.3 mg / g、6.4 mg / g、6.5 mg / g、6.6 mg / g、6.7 mg / g , 6.8 mg / g, 6.9 mg / g, 7 mg / g, 7.1 mg / g, 7.2 mg / g, 7.3 mg / g, 7.4 mg / g, 7.5 mg / g, 7.6 mg / g, 7.7 mg / g, 7.8 mg / g、7.9 mg / g、8 mg / g、8.1 mg / g、8.2 mg / g、8.3 mg / g、8.4 mg / g、8.5 mg / g、8.6 mg / g、8.7 mg / g、8.8 mg / g、8.9 mg / g、9 mg / g、9.1 mg / g、9.2 mg / g、9.3 mg / g、9.4 mg / g、9.5 mg / g、9.6 mg / g、9.7 mg / g、9.8 mg / g、9.9 mg / g、または10 mg / g。, 【0256】 In some embodiments, the pharmaceutical composition contains approximately 50 μg, approximately 75 μg, approximately 100 μg, approximately 150 μg, approximately 200 μg, approximately 250 μg, approximately 300 μg, approximately 350 μg, approximately 400 μg, approximately 450 μg, approximately 500 μg, approximately 550 μg, approximately 600 μg, approximately 650 μg, approximately 700 μg, approximately 750 μg, approximately 800 μg, approximately 850 μg, approximately 900 μg, approximately 950 μg, or approximately 1000 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 1 mg, about 1.2 mg, about 1.5 mg, about 2 mg, about 2.5 mg, or about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 150 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 300 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 500 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 600 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 900 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 1.2 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 3 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 10 mg of compound I or a pharmaceutically acceptable salt thereof. 【0257】 In some embodiments, the pharmaceutical composition contains 50 μg, 75 μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg, or 1000 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 1 mg, 1.2 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, or 10 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 150 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 300 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 500 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 600 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 900 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 1.2 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 3 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 10 mg of compound I or a pharmaceutically acceptable salt thereof. 【0258】 In some embodiments, the pharmaceutical composition contains approximately 50 μg, approximately 75 μg, approximately 100 μg, approximately 150 μg, approximately 200 μg, approximately 250 μg, approximately 300 μg, approximately 350 μg, approximately 400 μg, approximately 450 μg, approximately 500 μg, approximately 550 μg, approximately 600 μg, approximately 650 μg, approximately 700 μg, approximately 750 μg, approximately 800 μg, approximately 850 μg, approximately 900 μg, approximately 950 μg, or approximately 1000 μg of compound I. In some embodiments, the pharmaceutical composition contains about 1 mg, about 1.2 mg, about 1.5 mg, about 2 mg, about 2.5 mg, about 3 mg, about 3.5 mg, about 4 mg, about 4.5 mg, about 5 mg, about 5.5 mg, about 6 mg, about 6.5 mg, about 7 mg, about 7.5 mg, about 8 mg, about 8.5 mg, about 9 mg, about 9.5 mg, or about 10 mg of compound I. In some embodiments, the pharmaceutical composition contains about 150 μg of compound I. In some embodiments, the pharmaceutical composition contains about 300 μg of compound I. In some embodiments, the pharmaceutical composition contains about 500 μg of compound I. In some embodiments, the pharmaceutical composition contains about 600 μg of compound I. In some embodiments, the pharmaceutical composition contains about 900 μg of compound I. In some embodiments, the pharmaceutical composition contains about 1.2 mg of compound I. In some embodiments, the pharmaceutical composition contains about 3 mg of compound I. In some embodiments, the pharmaceutical composition contains about 10 mg of compound I. 【0259】 In some embodiments, the pharmaceutical composition contains 50 μg, 75 μg, 100 μg, 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg, or 1000 μg of compound I. In some embodiments, the pharmaceutical composition contains 1 mg, 1.2 mg, 1.5 mg, 2 mg, 2.5 mg, 3 mg, 3.5 mg, 4 mg, 4.5 mg, 5 mg, 5.5 mg, 6 mg, 6.5 mg, 7 mg, 7.5 mg, 8 mg, 8.5 mg, 9 mg, 9.5 mg, or 10 mg of compound I. In some embodiments, the pharmaceutical composition contains 150 μg of compound I. In some embodiments, the pharmaceutical composition contains 300 μg of compound I. In some embodiments, the pharmaceutical composition contains 500 μg of compound I. In some embodiments, the pharmaceutical composition contains 600 μg of compound I. In some embodiments, the pharmaceutical composition contains 900 μg of compound I. In some embodiments, the pharmaceutical composition contains 1.2 mg of compound I. In some embodiments, the pharmaceutical composition contains 3 mg of compound I. In some embodiments, the pharmaceutical composition contains 10 mg of compound I. 【0260】 In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is about 2 mg / g to about 4 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is about 2 mg / g to about 3 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is about 2 mg / g, about 2.1 mg / g, about 2.2 mg / g, about 2.3 mg / g, about 2.4 mg / g, about 2.5 mg / g, about 2.6 mg / g, about 2.7 mg / g, about 2.8 mg / g, about 2.9 mg / g, about 3 mg / g, about 3.1 mg / g, about 3.2 mg / g, about 3.3 mg / g, about 3.4 mg / g, about 3.5 mg / g, about 3.6 mg / g, about 3.7 mg / g, about 3.8 mg / g, about 3.9 mg / g, or about 4 mg / g. 【0261】 In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 2 mg / g to 4 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 2 mg / g to 3 mg / g. In some embodiments, the amount of compound I or a pharmaceutically acceptable salt in the composition is 2 mg / g, 2.1 mg / g, 2.2 mg / g, 2.3 mg / g, 2.4 mg / g, 2.5 mg / g, 2.6 mg / g, 2.7 mg / g, 2.8 mg / g, 2.9 mg / g, 3 mg / g, 3.1 mg / g, 3.2 mg / g, 3.3 mg / g, 3.4 mg / g, 3.5 mg / g, 3.6 mg / g, 3.7 mg / g, 3.8 mg / g, 3.9 mg / g, or 4 mg / g. 【0262】 In some embodiments, the amount of compound I in the composition is about 2 mg / g to about 4 mg / g. In some embodiments, the amount of compound I in the composition is about 2 mg / g to about 3 mg / g. In some embodiments, the amount of compound I in the composition is about 2 mg / g, about 2.1 mg / g, about 2.2 mg / g, about 2.3 mg / g, about 2.4 mg / g, about 2.5 mg / g, about 2.6 mg / g, about 2.7 mg / g, about 2.8 mg / g, about 2.9 mg / g, about 3 mg / g, about 3.1 mg / g, about 3.2 mg / g, about 3.3 mg / g, about 3.4 mg / g, about 3.5 mg / g, about 3.6 mg / g, about 3.7 mg / g, about 3.8 mg / g, about 3.9 mg / g, or about 4 mg / g. 【0263】 In some embodiments, the amount of compound I in the composition is 2 mg / g to 4 mg / g. In some embodiments, the amount of compound I in the composition is 2 mg / g to 3 mg / g. In some embodiments, the amount of compound I in the composition is 2 mg / g, 2.1 mg / g, 2.2 mg / g, 2.3 mg / g, 2.4 mg / g, 2.5 mg / g, 2.6 mg / g, 2.7 mg / g, 2.8 mg / g, 2.9 mg / g, 3 mg / g, 3.1 mg / g, 3.2 mg / g, 3.3 mg / g, 3.4 mg / g, 3.5 mg / g, 3.6 mg / g, 3.7 mg / g, 3.8 mg / g, 3.9 mg / g, or 4 mg / g. 【0264】 In some embodiments, the pharmaceutical composition contains about 150 μg, about 200 μg, about 250 μg, about 300 μg, about 350 μg, about 400 μg, about 450 μg, about 500 μg, about 550 μg, about 600 μg, about 650 μg, about 700 μg, about 750 μg, about 800 μg, about 850 μg, about 900 μg, about 950 μg, or about 1000 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, or about 3 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 150 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains about 3 mg of compound I or a pharmaceutically acceptable salt thereof. 【0265】 In some embodiments, the pharmaceutical composition contains 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg, or 1000 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 1 mg, 1.5 mg, 2 mg, 2.5 mg, or 3 mg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 150 μg of compound I or a pharmaceutically acceptable salt thereof. In some embodiments, the pharmaceutical composition contains 3 mg of compound I or a pharmaceutically acceptable salt thereof. 【0266】 In some embodiments, the pharmaceutical composition contains about 150 μg, about 200 μg, about 250 μg, about 300 μg, about 350 μg, about 400 μg, about 450 μg, about 500 μg, about 550 μg, about 600 μg, about 650 μg, about 700 μg, about 750 μg, about 800 μg, about 850 μg, about 900 μg, about 950 μg, or about 1000 μg of compound I. In some embodiments, the pharmaceutical composition contains about 1 mg, about 1.5 mg, about 2 mg, about 2.5 mg, or about 3 mg of compound I. In some embodiments, the pharmaceutical composition contains about 150 μg of compound I. In some embodiments, the pharmaceutical composition contains about 3 mg of compound I. 【0267】 In some embodiments, the pharmaceutical composition contains 150 μg, 200 μg, 250 μg, 300 μg, 350 μg, 400 μg, 450 μg, 500 μg, 550 μg, 600 μg, 650 μg, 700 μg, 750 μg, 800 μg, 850 μg, 900 μg, 950 μg, or 1000 μg of compound I. In some embodiments, the pharmaceutical composition contains 1 mg, 1.5 mg, 2 mg, 2.5 mg, or 3 mg of compound I. In some embodiments, the pharmaceutical composition contains 150 μg of compound I. In some embodiments, the pharmaceutical composition contains 3 mg of compound I. 【0268】 In some embodiments, the amount of monoglycerides in the glyceride is greater than about 30% by weight. In some embodiments, the amount of monoglycerides in the glyceride is from about 30% by weight to about 100% by weight. In some embodiments, the amount of monoglycerides in the glyceride is from about 30% by weight to about 90% by weight. In some embodiments, the amount of monoglycerides in the glyceride is from about 30% by weight to about 80% by weight. In some embodiments, the amount of monoglycerides in the glyceride is from about 30% by weight to about 70% by weight. In some embodiments, the monoglyceride content in the glyceride is from about 30% by weight to about 60% by weight. In some embodiments, the monoglyceride content in the glyceride is from about 30% by weight to about 50% by weight. In some embodiments, the monoglyceride content in the glyceride is from about 30% by weight to about 40% by weight. In some embodiments, the monoglyceride content in the glyceride is about 40% to about 100% by weight. In some embodiments, the monoglyceride content in the glyceride is about 40% to about 90% by weight. In some embodiments, the monoglyceride content in the glyceride is about 40% to about 80% by weight. In some embodiments, the monoglyceride content in the glyceride is about 40% to about 70% by weight. In some embodiments, the monoglyceride content in the glyceride is about 40% to about 60% by weight. In some embodiments, the monoglyceride content in the glyceride is about 40% to about 50% by weight. In some embodiments, the monoglyceride content in the glyceride is about 50% to about 100% by weight. In some embodiments, the monoglyceride content in the glyceride is about 50% to about 90% by weight. In some embodiments, the monoglyceride content in the glyceride is about 50% to about 80% by weight. In some embodiments, the monoglyceride content in the glyceride is about 50% to about 70% by weight. In some embodiments, the monoglyceride content in the glyceride is about 50% to about 60% by weight.In some embodiments, the monoglyceride content in the glyceride is about 60% to about 100% by weight. In some embodiments, the monoglyceride content in the glyceride is about 60% to about 90% by weight. In some embodiments, the monoglyceride content in the glyceride is about 60% to about 80% by weight. In some embodiments, the monoglyceride content in the glyceride is about 60% to about 70% by weight. In some embodiments, the monoglyceride content in the glyceride is about 70% to about 100% by weight. In some embodiments, the monoglyceride content in the glyceride is about 70% to about 90% by weight. In some embodiments, the monoglyceride content in the glyceride is about 70% to about 80% by weight. In some embodiments, the monoglyceride content in the glyceride is about 80% to about 100% by weight. In some embodiments, the monoglyceride content in the glyceride is about 80% by weight to about 90% by weight. In some embodiments, the monoglyceride content in the glyceride is about 90% by weight to about 100% by weight. In some embodiments, the monoglyceride content in the glyceride is about 30% by weight, about 35% by weight, about 40% by weight, about 45% by weight, about 50% by weight, about 55% by weight, about 60% by weight, about 65% by weight, about 70% by weight, about 75% by weight, about 80% by weight, about 85% by weight, about 90% by weight, about 95% by weight, or about 100% by weight. 【0269】 In some embodiments, the amount of monoglycerides in the glyceride exceeds 30% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 30% to 100% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 30% to 90% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 30% to 80% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 30% to 70% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 30% to 60% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 30% to 50% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 30% to 40% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 40% to 100% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 40% to 90% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 40% to 80% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 40% to 70% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 40% to 60% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 40% to 50% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 50% to 100% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 50% to 90% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 50% to 80% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 50% to 70% by weight. In some embodiments, the amount of monoglyceride in the glyceride is 50% to 60% by weight. In some embodiments, the amount of monoglyceride in the glyceride is 60% to 100% by weight.In some embodiments, the amount of monoglycerides in the glyceride is 60% to 90% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 60% to 80% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 60% to 70% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 70% to 100% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 70% to 90% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 70% to 80% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 80% to 100% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 80% to 90% by weight. In some embodiments, the amount of monoglycerides in the glyceride is 90% to 100% by weight. In some embodiments, the amount of monoglyceride in the glyceride is 30% by weight, 35% by weight, 40% by weight, 45% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, 70% by weight, 75% by weight, 80% by weight, 85% by weight, 90% by weight, 95% by weight, or 100% by weight. 【0270】 In some embodiments, one or more glycerides include one or more monoglycerides, diglycerides, triglycerides, or combinations thereof. Typical glycerides include, but are not limited to, glyceryl mono / dicaprylorate, glyceryl mono / dicaprylorate, glyceryl monocaprylate type 1, glyceryl monocaprylate type 1, glyceryl monocaprylorate type 1, glyceryl monolinoleate, their equivalents, and combinations thereof. In some embodiments, one or more glycerides include glyceryl monocaprylate. In some embodiments, one or more glycerides include glyceryl monolinoleate. In some embodiments, one or more glycerides include glyceryl monocaprylate and glyceryl monolinoleate. 【0271】 In some embodiments, the pharmaceutical composition contains one or more monoesters, diesters, or triesters (glycerides) of fatty acids bonded to glycerol groups, either alone or in combination with monoesters or diesters of fatty acids bonded to propylene glycol groups, at different chain lengths. In some embodiments, the pharmaceutical composition contains one or more monoesters, diesters, or triesters of fatty acids bonded to glycerol moieties (glycerides) at different chain lengths. In some embodiments, the pharmaceutical composition contains one or more monoesters, diesters, or triesters of fatty acids bonded to glycerol moieties (glycerides) at different chain lengths, in combination with monoesters or diesters of fatty acids bonded to propylene glycol groups. In some embodiments, the pharmaceutical composition contains one or more monoesters of fatty acids bonded to glycerol groups (glycerides) at different chain lengths. In some embodiments, the pharmaceutical composition contains one or more diesters of fatty acids bonded to glycerol groups (glycerides) at different chain lengths. In some embodiments, the pharmaceutical composition comprises one or more monoesters or diesters of fatty acids bonded to glycerol groups (glycerides) of different chain lengths. In some embodiments, the pharmaceutical composition comprises one or more monoesters of fatty acids bonded to propylene glycol groups. In some embodiments, the pharmaceutical composition comprises one or more diesters of fatty acids bonded to propylene glycol groups. 【0272】 Representative monoesters and diesters of fatty acids bonded to a glycerol group include, but are not limited to, glyceryl mono / dicaprylolate, glyceryl monocaprylate type 1, glyceryl monocaprylate type 1, glyceryl monocaprylolate type 1, glyceryl monolinoleate, or their equivalents. Representative monoesters and diesters of fatty acids bonded to a propylene glycol group (propylene glycol esters) include, but are not limited to, propylene glycol monocaprylate type II, propylene glycol monolaurate, propylene glycol dicaprylate / dicaprate, etc. 【0273】 In some embodiments, the pharmaceutical composition comprises one or more glycerides having different fatty acid chain length distributions. In some embodiments, the pharmaceutical composition comprises one or more medium-chain mono, di, or triglycerides (e.g., caproic acid (C6), caprylic acid (C8), caprylic acid (C10), lauric acid (C12)). In some embodiments, the pharmaceutical composition comprises one or more long-chain triglycerides (e.g., myristic acid (C14), palmitic acid (C16), stearic acid (C18), oleic acid (C18), linoleic acid (C18)). In some embodiments, the pharmaceutical composition comprises a combination of a medium-chain monoglyceride, a diglyceride, or a triglyceride and a long-chain triglyceride. 【0274】 In some embodiments, one or more glycerides in the pharmaceutical composition are selected from the group consisting of glyceryl monocaprylate, glyceryl monolinoleate, and combinations thereof. In some embodiments, the glyceride is glyceryl monocaprylate. In some embodiments, the glyceride is glyceryl monolinoleate. In some embodiments, the pharmaceutical composition contains glyceryl monocaprylate and glyceryl monolinoleate. 【0275】 In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 20% to about 80% by weight. In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 20% to about 70% by weight. In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 20% to about 60% by weight. In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 20% to about 50% (by weight). In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 20% to about 40% (by weight). In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 20% to about 30% (by weight). In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 30% to about 80% by weight. In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 30% to about 70% by weight. In some embodiments, glyceryl monocaprylate is present in an amount ranging from about 30% to about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 30% to about 50% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 30% to about 40% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 40% to about 80% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 40% to about 70% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 40% to about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 40% to about 50% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 50% to about 80% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 50% to about 70% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 50% to about 60% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 60% to about 80% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 60% to about 70% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from about 70% to about 80% by weight.In some embodiments, glyceryl monocaprylate is contained in amounts of approximately 20%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, and 80% by weight. In some embodiments, glyceryl monocaprylate is present in amounts of approximately 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 56%, 57%, 58%, 59%, 61%, 62%, 63%, and 64% by weight. In some embodiments, glyceryl monocaprylate is present in an amount of approximately 49% by weight. In some embodiments, glyceryl monocaprylate is present in an amount of approximately 50% by weight. In some embodiments, glyceryl monocaprylate is present in an amount of approximately 51% by weight. In some embodiments, glyceryl monocaprylate is present in amounts of approximately 49.5%, 49.6%, 49.7%, 49.8%, 49.9%, 50.0%, 50.1%, 50.2%, 50.3%, 50.4%, and 50.5% by weight. In some embodiments, glyceryl monocaprylate is present in amounts of approximately 49.8% by weight. In some embodiments, glyceryl monocaprylate is present in amounts of approximately 59% by weight. In some embodiments, glyceryl monocaprylate is present in amounts of approximately 60% by weight. In some embodiments, glyceryl monocaprylate is present in amounts of approximately 61% by weight. In some embodiments, the amount of glyceryl monocaprylate is approximately 59.5%, 59.6%, 59.7%, 59.8%, 59.9%, 60.0%, 60.1%, 60.2%, and 60.3% (by weight). In some embodiments, the amount of glyceryl monocaprylate is approximately 59.8% by weight. 【0276】 In some embodiments, the amount of glyceryl monocaprylate ranges from 20% to 80% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 20% to 70% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 20% to 60% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 20% to 50% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 20% to 40% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 20% to 30% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 30% to 80% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 30% to 70% by weight. In some embodiments, the amount of glyceryl monocaprylate ranges from 30% to 60% by weight. In some embodiments, the amount of glyceryl monocaprylate is 30-50% by weight. In some embodiments, the amount of glyceryl monocaprylate is 30-40% by weight. In some embodiments, the amount of glyceryl monocaprylate is 40-80% by weight. In some embodiments, the amount of glyceryl monocaprylate is 40-70% by weight. In some embodiments, the amount of glyceryl monocaprylate is 40-60% by weight. In some embodiments, the amount of glyceryl monocaprylate is 40-50% by weight. In some embodiments, the amount of glyceryl monocaprylate is in the range of 50% to 80% by weight. In some embodiments, the amount of glyceryl monocaprylate is in the range of 50% to 70% by weight. In some embodiments, the amount of glyceryl monocaprylate is in the range of 50% to 60% by weight. In some embodiments, the amount of glyceryl monocaprylate is in the range of 60% to 80% by weight. In some embodiments, the amount of glyceryl monocaprylate is 60% to 70% by weight. In some embodiments, the amount of glyceryl monocaprylate is 70% to 80% by weight. In some embodiments, the amount of glyceryl monocaprylate is 20%, 30%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, and 80% (by weight).In some embodiments, glyceryl monocaprylate is contained in weight ratios of 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 56%, 57%, 58%, 59%, 61%, 62%, 63%, and 64%. In some embodiments, glyceryl monocaprylate is present in an amount of 49% by weight. In some embodiments, glyceryl monocaprylate is present in an amount of 50% by weight. In some embodiments, glyceryl monocaprylate is present in an amount of 51% by weight. In some embodiments, glyceryl monocaprylate is present in an amount of 49.5%, 49.6%, 49.7%, 49.8%, 49.9%, 50.0%, 50.1%, 50.2%, 50.3%, 50.4%, and 50.5% (by weight). In some embodiments, glyceryl monocaprylate is present in an amount of 49.8% by weight. In some embodiments, the amount of glyceryl monocaprylate is 59% by weight. In some embodiments, the amount of glyceryl monocaprylate is 60% by weight. In some embodiments, the amount of glyceryl monocaprylate is 61% by weight. In some embodiments, the amount of glyceryl monocaprylate is 59.5%, 59.6%, 59.7%, 59.8%, 59.9%, 60.0%, 60.1%, 60.2%, and 60.3% (by weight). In some embodiments, the amount of glyceryl monocaprylate is 59.8% by weight. 【0277】 In some embodiments, the amount of glyceryl monolinoleate ranges from about 10% to about 30% by weight. In some embodiments, the amount of glyceryl monolinoleate ranges from about 15% to about 30% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 15% to about 25% by weight (w / w). In some embodiments, the amount of glyceryl monolinoleate is about 15% to about 20% by weight (w / w). In some embodiments, the amount of glyceryl monolinoleate is about 20% to about 30% by weight (w / w). In some embodiments, the amount of glyceryl monooleate is about 25% to about 30% (by weight). In some embodiments, the amount of glyceryl monooleate is about 10%, 15%, 20%, 25%, and 30% (by weight). In some embodiments, the amount of glyceryl monooleate is about 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, and 25% (by weight). In some embodiments, the amount of glyceryl monooleate is about 19%. In some embodiments, the amount of glyceryl monolinoleate is about 20% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 21% by weight. In some embodiments, the amount of glyceryl monooleate is in the range of about 19.5% by weight, about 19.6% by weight, about 19.7% by weight, about 19.8% by weight, about 19.9% ​​by weight, about 20.1% by weight, about 20.2% by weight, about 20.3% by weight, about 20.4% by weight, and about 20.5% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 19.8% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 19.9% ​​by weight. In some embodiments, the amount of glyceryl monolinoleate is about 20% by weight. In some embodiments, the amount of glyceryl monooleate is about 22.0%, about 22.1%, about 22.2%, about 22.3%, about 22.4%, about 22.5%, about 22.6%, about 22.7%, about 22.8%, and about 22.9% (by weight). In some embodiments, the amount of glyceryl monolinoleate is about 22.3% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 22.4% by weight. In some embodiments, the amount of glyceryl monolinoleate is about 22.5% by weight. 【0278】 In some embodiments, the amount of glyceryl monooleate is 10% to 30% by weight. In some embodiments, the amount of glyceryl monooleate is 15% to 30% by weight. In some embodiments, the amount of glyceryl monooleate is 15% to 25% by weight. In some embodiments, the amount of glyceryl monolinoleate is in the range of 15% to 20% by weight. In some embodiments, the amount of glyceryl monolinoleate is in the range of 20% to 30% by weight. In some embodiments, the amount of glyceryl monolinoleate is in the range of 25% to 30% by weight. In some embodiments, the amount of glyceryl monooleate is 10%, 15%, 20%, 25%, and 30% (by weight). In some embodiments, the amount of glyceryl monooleate is 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, and 25% (by weight). In some embodiments, the amount of glyceryl monooleate is 19%. In some embodiments, the amount of glyceryl monolinoleate is 20% by weight. In some embodiments, the amount of glyceryl monolinoleate is 21% by weight. In some embodiments, the amount of glyceryl monooleate is 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.1%, 20.2%, 20.3%, 20.4%, and 20.5% w / w. In some embodiments, the amount of glyceryl monolinoleate is 19.8% by weight. In some embodiments, the amount of glyceryl monolinoleate is 19.9% ​​by weight. In some embodiments, the amount of glyceryl monolinoleate is 20% by weight. In some embodiments, the amount of glyceryl monooleate is in the range of 22.0%, 22.1%, 22.2%, 22.3%, 22.4%, 22.5%, 22.6%, 22.7%, 22.8%, and 22.9% (by weight). In some embodiments, the amount of glyceryl monolinoleate is 22.3% by weight. In some embodiments, the amount of glyceryl monolinoleate is 22.4% by weight. In some embodiments, the amount of glyceryl monolinoleate is 22.5% by weight. 【0279】 In some embodiments, the pharmaceutical composition further comprises a surfactant. In some embodiments, the surfactant is stearoyl polyoxyl-32 glyceride. In some embodiments, the surfactant is lauroyl polyoxyl-32 glyceride. 【0280】 In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 5.0% to about 20% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 5.0% to about 15% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is in a weight ratio (w / w) of about 5.0% to about 10%. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is in a weight ratio (w / w) of about 5.0% to about 9.0%. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 5.0% to about 8.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 5.0% to about 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 6.0% to about 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 6.0% to about 9.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 6.0% to about 8.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 6.0% to about 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 7.0% to about 10.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 7.0% to about 9.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 7.0% to about 8.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from about 7.0% to about 7.5% by weight. In some embodiments, the weight ratio (w / w) of stearoyl polyoxyl-32 glyceride is about 7.0%, about 7.1%, about 7.2%, about 7.3%, about 7.4%, about 7.5%, about 7.6%, about 7.7%, about 7.8%, about 7.9%, and about 8.0%. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 7.4% by weight.In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 15% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is about 20% by weight. 【0281】 In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 5.0% to 20% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 5.0% to 15% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 5.0% to 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 5.0% to 9.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 5.0% to 8.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 5.0% to 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 6.0% to 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 6.0% to 9.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 6.0% to 8.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 6.0% to 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 7.0% to 10.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 7.0% to 9.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride ranges from 7.0% to 8.0% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 7.0% to 7.5% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, and 8.0% by weight (w / w). In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 7.4% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 7.5% by weight.In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 10% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 15% by weight. In some embodiments, the amount of stearoyl polyoxyl-32 glyceride is 20% by weight. 【0282】 In some embodiments, the amount of lauroyl polyoxyl-32 glyceride ranges from about 5.0% to about 20% by weight. In some embodiments, the amount of lauroyl polyoxyl-32 glyceride ranges from about 5.0% to about 15% by weight. In some embodiments, the amount of lauroyl polyoxyl-32 glyceride ranges from about 5.0% to about 10% by weight. In some embodiments, the amount of lauroyl polyoxyl-32 glyceride ranges from about 5.0% to about 9.0% by weight. In some embodiments, the amount of lauroyl polyoxyl-32 glyceride ranges from about 5.0% to about 8.0% by weight. In some embodiments, the amount of lauroyl polyoxyl-32 glyceride ranges from about 5.0% to about 7.5% by weight. In some embodiments, the amount of lauroyl polyoxyl-32 glyceride ranges from about 6.0% to about 10% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from about 6.0% to about 9.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from about 6.0% to about 8.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from about 6.0% to about 7.5% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from about 7.0% to about 10.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from about 7.0% to about 9.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from about 7.0% to about 8.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from about 7.0% to about 7.5% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is about 7.0%, about 7.1%, about 7.2%, about 7.3%, about 7.4%, about 7.5%, about 7.6%, about 7.7%, about 7.8%, about 7.9%, and about 8.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is about 7.4% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is about 7.5% by weight.In some embodiments, the amount of lauroyl polyoxy-32 glyceride is about 10% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is about 15% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is about 20% by weight. 【0283】 In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from 5.0% to 20% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from 5.0% to 15% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from 5.0% to 10% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from 5.0% to 9.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from 5.0% to 8.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from 5.0% to 7.5% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride ranges from 6.0% to 10% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is in the range of 6.0% to 9.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is in the range of 6.0% to 8.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is in the range of 6.0% to 7.5% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is in the range of 7.0% to 10.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is in the range of 7.0% to 9.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is in the range of 7.0% to 8.0% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is in the range of 7.0% to 7.5% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is 7.0%, 7.1%, 7.2%, 7.3%, 7.4%, 7.5%, 7.6%, 7.7%, 7.8%, 7.9%, and 8.0% by weight (w / w). In some embodiments, the amount of lauroyl polyoxy-32 glyceride is 7.4% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is 7.5% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is 10% by weight.In some embodiments, the amount of lauroyl polyoxy-32 glyceride is 15% by weight. In some embodiments, the amount of lauroyl polyoxy-32 glyceride is 20% by weight. 【0284】 In some embodiments, the pharmaceutical composition further comprises a surfactant (e.g., vitamin E TPGS). In some embodiments, the surfactant is present in an amount of about 10% to about 30% (by weight). In some embodiments, the surfactant is present in an amount of about 10% to about 25% (by weight). In some embodiments, the surfactant is present in an amount of about 10% to about 20% (by weight). In some embodiments, the surfactant is present in an amount of about 15% to about 30% (by weight). In some embodiments, the surfactant is present in an amount of about 15% to about 25% (by weight). In some embodiments, the surfactant is present in an amount ranging from about 15% to about 20% by weight. In some embodiments, the surfactant is present in a weight ratio of approximately 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30%. In some embodiments, the surfactant is present in a weight ratio of approximately 19.5% by weight, 19.6% by weight, 19.7% by weight, 19.8% by weight, 19.9% ​​by weight, 20.1% by weight, 20.2% by weight, 20.3% by weight, 20.4% by weight, or 20.5% by weight. In some embodiments, the surfactant is present in an amount of approximately 19.9% ​​by weight. In some embodiments, the surfactant is present in an amount of approximately 20.0% by weight. In some embodiments, the surfactant is present in an amount of approximately 20.1% by weight. 【0285】 In some embodiments, the pharmaceutical composition further comprises a surfactant (e.g., vitamin E TPGS). In some embodiments, the surfactant is present in an amount of 10% to 30% (by weight). In some embodiments, the surfactant is present in an amount of 10% to 25% (by weight). In some embodiments, the surfactant is present in an amount of 10% to 20% (by weight). In some embodiments, the surfactant is present in an amount ranging from 15% to 30% by weight. In some embodiments, the surfactant is present in an amount ranging from 15% to 25% by weight. In some embodiments, the surfactant is present in an amount ranging from 15% to 20% by weight. In some embodiments, the surfactant is present in a weight ratio of 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30%. In some embodiments, the amount of surfactant is 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.1%, 20.2%, 20.3%, 20.4%, and 20.5% (by weight). In some embodiments, the amount of surfactant is 19.9% ​​by weight. In some embodiments, the amount of surfactant is 20.0% by weight. In some embodiments, the amount of surfactant is 20.1% by weight. 【0286】 In some embodiments, the pharmaceutical composition further comprises vitamin E TPGS. In some embodiments, the amount of vitamin E TPGS is about 10% to about 30% by weight. In some embodiments, the amount of vitamin E TPGS is 10% to about 25% by weight. In some embodiments, the amount of vitamin E TPGS is about 10% to about 20% by weight. In some embodiments, the amount of vitamin E TPGS is about 15% to about 30% by weight. In some embodiments, the amount of vitamin E TPGS is about 15% to about 25% by weight. In some embodiments, the amount of vitamin E TPGS is about 15% to about 20% (by weight). In some embodiments, vitamin E TPGS is contained in a weight ratio of approximately 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30%. In some embodiments, the amount of vitamin E TPGS is approximately 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.1%, 20.2%, 20.3%, 20.4%, or 20.5% (by weight). In some embodiments, the amount of vitamin E TPGS is approximately 19.9% ​​by weight. In some embodiments, the amount of vitamin E TPGS is approximately 20.0% by weight. In some embodiments, the amount of vitamin E TPGS is approximately 20.1% by weight. 【0287】 In some embodiments, the amount of vitamin E TPGS is 10% to 30% by weight. In some embodiments, the amount of vitamin E TPGS is 10% to 25% by weight. In some embodiments, the amount of vitamin E TPGS is 10% to 20% by weight. In some embodiments, the amount of vitamin E TPGS is in the range of 15% to 30% by weight. In some embodiments, the amount of vitamin E TPGS is in the range of 15% to 25% by weight. In some embodiments, the amount of vitamin E TPGS is in the range of 15% to 20% by weight. In some embodiments, the content of vitamin E TPGS is in the weight ratio of 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, or 30%. In some embodiments, the amount of vitamin E TPGS is 19.5%, 19.6%, 19.7%, 19.8%, 19.9%, 20.1%, 20.2%, 20.3%, 20.4%, and 20.5% (by weight). In some embodiments, the amount of vitamin E TPGS is 19.9% ​​by weight. In some embodiments, the amount of vitamin E TPGS is 20.0% by weight. In some embodiments, the amount of vitamin E TPGS is 20.1% by weight. 【0288】 In some embodiments, the pharmaceutical composition further comprises antioxidants (e.g., butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tocopherol, tocopherol acetate, etc.). 【0289】 In some embodiments, the antioxidant content is approximately 0.005% to approximately 0.015% (by weight). In some embodiments, the antioxidant content is approximately 0.005% to approximately 0.010% (by weight). In some embodiments, the amount of antioxidant is approximately 0.010% to approximately 0.015% by weight. In some embodiments, the amount of antioxidant is approximately 0.008% to approximately 0.012% by weight. In some embodiments, the amount of antioxidant is approximately 0.005%, approximately 0.006%, approximately 0.007%, approximately 0.008%, approximately 0.009%, approximately 0.010%, approximately 0.011%, approximately 0.012%, approximately 0.013%, approximately 0.014%, and approximately 0.015% by weight. In some embodiments, the amount of antioxidant is approximately 0.008% by weight. In some embodiments, the amount of antioxidant is about 0.009% by weight. In some embodiments, the amount of antioxidant is about 0.010% by weight. In some embodiments, the amount of antioxidant is about 0.011% by weight. In some embodiments, the amount of antioxidant is from about 0.012% to about 0.015% by weight. 【0290】 In some embodiments, the pharmaceutical composition further includes an antioxidant such as butylated hydroxyanisole (BHA). In some embodiments, the amount of antioxidant is 0.005% to 0.015% (by weight). In some embodiments, the amount of antioxidant is 0.005% to 0.010% (by weight). In some embodiments, the antioxidant content is 0.010% to 0.015% by weight. In some embodiments, the antioxidant content is 0.008% to 0.012% by weight. In some embodiments, the antioxidant content is 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.010%, 0.011%, 0.012%, 0.013%, 0.014%, 0.015% (by weight). In some embodiments, the antioxidant is 0.008% (by weight). In some embodiments, the antioxidant is 0.009% by weight. In some embodiments, the antioxidant is 0.010% by weight. In some embodiments, the antioxidant is 0.011% by weight. In some embodiments, the antioxidant is 0.012% to 0.015% by weight. 【0291】 In some embodiments, the amount of butylated hydroxyanisole (BHA) is about 0.005% to about 0.015% (by weight). In some embodiments, the amount of butylated hydroxyanisole (BHA) is about 0.005% to about 0.010% (by weight). In some embodiments, the amount of butylated hydroxyanisole (BHA) is about 0.010% to about 0.015% (by weight). In some embodiments, the amount of butylated hydroxyanisole (BHA) is about 0.008% to about 0.012% (by weight). In some embodiments, butylated hydroxyanisole (BHA) is present in weight ratios of approximately 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.010%, 0.011%, 0.012%, 0.013%, 0.014%, and 0.015%. In some embodiments, butylated hydroxyanisole (BHA) is present in weight ratios of approximately 0.008%. In some embodiments, butylated hydroxyanisole (BHA) is present in weight ratios of approximately 0.009%. In some embodiments, butylated hydroxyanisole (BHA) is present in weight ratios of approximately 0.010%. In some embodiments, butylated hydroxyanisole (BHA) is present in weight ratios of approximately 0.011%. In some embodiments, butylated hydroxyanisole (BHA) is present in weight ratios of approximately 0.012% to approximately 0.015%. 【0292】 In some embodiments, the pharmaceutical composition further includes an antioxidant such as butylated hydroxyanisole (BHA). In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.005% to 0.015% (by weight). In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.005% to 0.010% (by weight). In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.010% to 0.015% (by weight). In some embodiments, the content of butylated hydroxyanisole (BHA) is 0.008% to 0.012% (by weight). In some embodiments, the butylated hydroxyanisole (BHA) content is 0.005%, 0.006%, 0.007%, 0.008%, 0.009%, 0.010%, 0.011%, 0.012%, 0.013%, 0.014%, and 0.015% by weight. In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.008% by weight. In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.009% by weight. In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.010% by weight. In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.011% (by weight). In some embodiments, the amount of butylated hydroxyanisole (BHA) is 0.012% to 0.015% (by weight). 【0293】 In some embodiments, the pharmaceutical composition contains about 0.3% by weight of compound I, about 60% by weight of glyceryl monocaprylate, about 20% by weight of glyceryl monolinoleate, about 20% by weight of vitamin E TPGS, and about 0.01% by weight of butylated hydroxyanisole. In some embodiments, the pharmaceutical composition contains 0.3% by weight of compound I, 60% by weight of glyceryl monocaprylate, 20% by weight of glyceryl monolinoleate, 20% by weight of vitamin E TPGS, and 0.01% by weight of butylated hydroxyanisole. In some embodiments, the pharmaceutical composition contains 0.3% compound I, 59.8% glyceryl monocaprylate, 19.9% ​​glyceryl monolinoleate, 19.9% ​​vitamin E TPGS, and 0.01% butylated hydroxyanisole. 【0294】 In some embodiments, the pharmaceutical composition comprises about 0.3% by weight of Compound I, about 50% by weight of glyceryl monocaprylate, about 22.5% by weight of glyceryl monolinoleate, about 20% by weight of vitamin E TPGS, about 7.5% by weight of stearoyl polyoxyl-32 glyceride, and about 0.01% by weight of butylated hydroxyanisole. In some embodiments, the pharmaceutical composition contains 0.3% by weight of Compound I, 50% by weight of glyceryl monocaprylate, 22.5% by weight of glyceryl monolinoleate, 20% by weight of vitamin E TPGS, 7.5% w / w stearoyl polyoxyl-32 glyceride, and 0.01% w / w butylated hydroxyanisole. In some embodiments, the pharmaceutical composition comprises about 0.3% w / w Compound I, 49.8% w / w Glyceryl Monocaprylate, 22.4% w / w Glyceryl Monolinoleate, 19.9% ​​w / w Vitamin E TPGS, 7.5% w / w Stearoyl Polyoxyl-32 Glyceride, and 0.01% w / w Butylated Hydroxyanisole. 【0295】 In some embodiments, the pharmaceutical composition is an oral dosage form. In some embodiments, the pharmaceutical composition is a lipid preparation. In some embodiments, the oral dosage form is a soft gelatin capsule, a hard shell capsule, or an oral liquid. In some embodiments, the oral dosage form is a soft gelatin capsule. In some embodiments, the oral dosage form is a hard shell capsule. In some embodiments, the oral dosage form is an oral liquid. 【0296】 In some respects, this disclosure relates to Compound I [ka] (Compound I), The present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Here, after administration of the pharmaceutical composition to a subject, the pharmaceutical composition provides one or more of the following pharmacokinetic parameters: a) C in the range of approximately 8 to approximately 25 ng / mL max ; b) AUC in the range of approximately 100 to 450 ng*h / mL last ; c) A in the range of approximately 100 to 500 ng·h / mL UC(inf) ; d)t max The duration is in the range of approximately 2 to 8 hours; or e) Approximately 70-100% bioavailability. 【0297】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of about 9 to about 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of about 11 to about 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition is in the range of about 12 to about 25 ng / mL.C(max) Provides. In some embodiments, the pharmaceutical composition is in the range of about 13 to about 25 ng / mL. C(max) Provides. In some embodiments, the pharmaceutical composition contains C in the range of about 14 to about 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition is in the range of about 15 to about 25 ng / mL. C(max) To provide. 【0298】 In some embodiments, the pharmaceutical composition provides a C(max) of approximately 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23.0, 23.5, 24, 24.5, or 25 ng / mL. In some embodiments, the pharmaceutical composition provides a C(max) of approximately 12, 12.1, 12.2, 12.3, 12.4, 12.6, 12.7, 12.8, 12.9, or 13.0 ng / mL. max It provides 15.1, 15.2, 15.3, 15.4, 15.6, 15.7, 15.8, 15.9, or 16 ng / mL. In some embodiments, the drug composition is approximately 12 ng / mL of C max It provides. In some embodiments, the drug composition contains about 12.1 ng / mL of C max It provides. In some embodiments, the drug composition contains about 12.2 ng / mL of C max It provides. In some embodiments, the drug composition contains about 12.3 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains about 12.4 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains about 12.5 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains about 12.6 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains approximately 12.7 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains about 12.8 ng / mL of C.max Provides. In some embodiments, the pharmaceutical composition contains about 12.9 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains approximately 13 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains about 15 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains about 15.1 ng / mL of C max It provides. In some embodiments, the drug composition contains about 15.2 ng / mL of C max It provides. In some embodiments, the drug composition contains about 15.3 ng / mL of C max Provides. In some embodiments, the drug composition contains about 15.4 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains approximately 15.5 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains approximately 15.6 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains approximately 15.7 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains about 15.8 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains about 15.9 ng / mL of C. max In some embodiments, the pharmaceutical composition contains approximately 16 ng / mL of C. max To provide. 【0299】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of 9 to 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of 10-25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of 11 to 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of 12 to 25 ng / mL. maxProvides. In some embodiments, the pharmaceutical composition contains C in the range of 13 to 25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of 14-25 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains C in the range of 15 to 25 ng / mL. max To provide. 【0300】 In some embodiments, the pharmaceutical composition provides C(max) of 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 14.5, 15, 15.5, 16, 16.5, 17, 17.5, 18, 18.5, 19, 19.5, 20, 20.5, 21, 21.5, 22, 22.5, 23.0, 23.5, 24, 24.5, or 25 ng / mL. In some embodiments, the pharmaceutical composition provides C(max) of 12, 12.1, 12.2, 12.3, 12.4, 12.6, 12.7, 12.8, 12.9, or 13.0 ng / mL. max Provides. In some embodiments, the pharmaceutical composition contains 15.1, 15.2, 15.3, 15.4, 15.6, 15.7, 15.8, 15.9, or 16 ng / mL of C. max Provides. In some embodiments, the pharmaceutical composition contains 12 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains 12.1 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains 12.2 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains 12.3 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains 12.4 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains 12.5 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains 12.6 ng / mL of C max Provides. In some embodiments, the pharmaceutical composition contains 12.7 ng / mL of C maxTo provide. In some embodiments, the pharmaceutical composition has a C of 12.8 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 12.9 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 13 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.1 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.2 ng / mL( max) To provide. In some embodiments, the pharmaceutical composition has a C of 15.3 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.4 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.5 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.6 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.7 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.8 ng / mL max To provide. In some embodiments, the pharmaceutical composition has a C of 15.9 ng / ml max To provide. In some embodiments, the pharmaceutical composition has a C of 16 ng / ml max To provide. 【0301】 In some embodiments, C max is the geometric mean C max is. 【0302】 In some embodiments, C max range is the geometric mean C max range. 【0303】 In some embodiments, the pharmaceutical composition has a t in the range of about 2 hours to about 8 hours maxTo provide. In some embodiments, the pharmaceutical composition has a t in the range of about 3 hours to about 8 hours max To provide. In some embodiments, the pharmaceutical composition has a t in the range of about 4 hours to about 8 hours max To provide. In some embodiments, the pharmaceutical composition has a t in the range of about 5 hours to about 8 hours max To provide. In some embodiments, the pharmaceutical composition has a t in the range of about 6 hours to about 8 hours max To provide. In some embodiments, the pharmaceutical composition has a t in the range of about 7 hours to about 8 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 3 hours to about 6 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 2 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 2.5 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 3 hours t(max) To provide. In some embodiments, the pharmaceutical composition has a t of about 3.5 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 4 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 4.5 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 5 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 5.5 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 6 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 6.5 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 7 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 7.5 hours max To provide. In some embodiments, the pharmaceutical composition has a t of about 8 hours max To provide. 【0304】 In some embodiments, the pharmaceutical composition has a t in the range of 2 hours to 8 hours maxProvides. In some embodiments, the pharmaceutical composition is administered over a period of 3 to 8 hours. max Provides. In some embodiments, the pharmaceutical composition is administered over a period of 4 to 8 hours. max Provides. In some embodiments, the pharmaceutical composition is administered over a period of 5 to 8 hours. max Provides. In some embodiments, the pharmaceutical composition is administered over a period of 6 to 8 hours. max Provides. In some embodiments, the pharmaceutical composition is administered over a period of 7 to 8 hours. max Provides. In some embodiments, the pharmaceutical composition is administered over a period of 3 to 6 hours. max Provides. In some embodiments, the pharmaceutical composition is 2 hours t max Provides a maximum time to reach 2.5 hours (t) in some embodiments. max) Provides a maximum reach of 3 hours in some embodiments. ( t max) Provides a maximum time to reach 3.5 hours (t) in some embodiments. max) Provides a maximum reach of 4 hours in some embodiments. ( t (max )) provides. In some embodiments, the pharmaceutical composition provides 4.5 hours of t max Provides. In some embodiments, the pharmaceutical composition is 5 hours t max Provides. In some embodiments, the pharmaceutical composition provides 5.5 hours of t max Provides. In some embodiments, the pharmaceutical composition is 6 hours t max Provides. In some embodiments, the pharmaceutical composition is 6.5 hours t max Provides. In some embodiments, the pharmaceutical composition is 7 hours t max Provides. In some embodiments, the pharmaceutical composition is 7.5 hours t max Provides. In some embodiments, the pharmaceutical composition is 8 hours t max To provide. 【0305】 In some embodiments, tmax t is the geometric mean max That is the case. 【0306】 In some embodiments, t max The range is the geometric mean t max It is within the range of [the specified range]. 【0307】 In some embodiments, the pharmaceutical composition is used for a period ranging from about 20 hours to about 200 hours. last Provides. In some embodiments, the pharmaceutical composition provides about 20 hours, about 24 hours, about 28 hours, about 32 hours, about 36 hours, about 40 hours, about 44 hours, about 48 hours, about 52 hours, about 56 hours, about 60 hours, about 64 hours, about 68 hours, about 72 hours, about 76 hours, about 80, about 84, about 88, about 92, about 96, about 100, about 104, about 108, about 112, about 116, about 120, about 124, about 128, about 132, about 136, about 140, about 144, about 148, about 152, about 156, about 160, about 164, about 168, about 172, about 176, about 180, about 184, about 188, about 192, about 196, or about 200 hours. 【0308】 In some embodiments, the pharmaceutical composition is 20 to 200 hours t last The pharmaceutical composition is provided. In some embodiments, the pharmaceutical composition is 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92, 96, 100, 104, 108, 112, 116, 120, 124, 128, 132, 136, 140, 144, 148, 152, 156, 160, 164, 168, 172, 176, 180, 184, 188, 192, 196, or 200 hours. 【0309】 In some embodiments, t last is the geometric mean t last That is the case. 【0310】 In some embodiments, t last The range is the geometric mean t last It is within the range of [the specified range]. 【0311】 In some embodiments, the pharmaceutical composition has a concentration ranging from about 100 to about 450 ng*h / mL AUC(last) Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of about 125 to about 400 ng*h / mL. last Provides: In some embodiments, the pharmaceutical composition has an AUC in the range of about 150 to about 350 ng*h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of about 175 to about 300 ng*h / mL. last In some embodiments, the drug composition is provided in an AU range of about 200 to about 275 ng·h / ml. C(ラスト) In some embodiments, the drug composition has an AUC in the range of about 225 to about 250 ng·h / ml. ラスト To provide. 【0312】 In some embodiments, the pharmaceutical composition provides an AUC of approximately 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 245, 246, 247, 248, 249, or 250 ng*h / mL. In some embodiments, the pharmaceutical composition provides an AUC of approximately 225 ng*h / mL. last In some embodiments, the drug composition contains approximately 226 ng*h / mL of A UC(last) It provides. In some embodiments, the drug composition has an AUC of about 227 ng*h / mL. last Provides a pharmaceutical composition with an AUC of approximately 228 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of approximately 228 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition contains approximately 229 ng·h / mL of A UC(last) Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 230 ng·h / mL. last In some embodiments, the pharmaceutical composition has an AUC of approximately 231 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition is approximately 232 ng·h / mL AUC(last)Provides. In some embodiments, the pharmaceutical composition contains approximately 233 ng·h / mL of A UC(last) Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 234 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 235 ng·h / mL. last In some embodiments, the pharmaceutical composition has an AUC of approximately 236 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 237 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition is approximately 238 ng·h / mL AUC(last) In some embodiments, the pharmaceutical composition has an AUC of approximately 239 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately ng*h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 241 ng*h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 242 ng*h / mL. last In some embodiments, the pharmaceutical composition has an AUC of approximately 243 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition contains approximately 244 ng·h / mL of A UC(last) Provides. In some embodiments, the pharmaceutical composition contains approximately 245 ng·h / mL of A UC(last) In some embodiments, the pharmaceutical composition has an AUC of approximately 246 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 247 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition contains approximately 248 ng·h / mL of A UC(last) Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 249 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition is approximately 250 ng·h / mL AUC(last) To provide. 【0313】 In some embodiments, the pharmaceutical composition has an AUC in the range of 100 to 450 ng*h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of 125 to 400 ng*h / mL. last Provides. In some embodiments, the pharmaceutical composition is in the range of 150 to 350 ng·h / ml. AUC(ラスト) Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of 175 to 300 ng·h / ml. ラスト Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of 200 to 275 ng*h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of 225 to 250 ng*h / mL. last To provide. 【0314】 In some embodiments, the pharmaceutical composition provides an AUC of 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 245, 246, 247, 248, 249, and 250 ng*h / mL. In some embodiments, the drug composition has an AUC of 225 ng*h / mL. last In some embodiments, the pharmaceutical composition has an AUC of 226 ng*h / mL. last The pharmaceutical composition provides an AUC of 227 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC of 227 ng*h / mL. last The pharmaceutical composition provides an AUC of 228 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC of 228 ng*h / mL. last Provides a pharmaceutical composition with an AUC of 229 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 229 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of 230 ng·h / mL. last Provides a pharmaceutical composition with an AUC of 231 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 231 ng·h / mL. last Provides a pharmaceutical composition with an AUC of 232 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 232 ng·h / mL. lastProvides a pharmaceutical composition with an AUC of 233 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 233 ng·h / mL. last Provides a pharmaceutical composition with an AUC of 234 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 234 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of 235 ng·h / mL. last In some embodiments, the pharmaceutical composition has an AUC of 236 ng·h / mL. last Provides a pharmaceutical composition with an AUC of 237 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 237 ng·h / mL. last Provides a pharmaceutical composition with an AUC of 238 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 238 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of 239 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of 240 ng·h / mL. last Provides a pharmaceutical composition with an AUC of 241 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 241 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of 242 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of 243 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition is AUC last The AUC is 244 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC last The AUC is 245 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC of 245 ng*h / mL. last The AUC is 246 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC of 247 ng·h / mL. last Provides. In some embodiments, the pharmaceutical composition has an AUC of 248 ng·h / mL. last Provides a pharmaceutical composition with an AUC of 249 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 249 ng·h / mL. last The pharmaceutical composition provides an AUC of 250 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC of 250 ng*h / mL. last To provide. 【0315】 In some embodiments, AUC last This is the geometric mean AUC. last That is the case. 【0316】 In some embodiments, AUC last The range is the geometric mean AUC. last It is within the range of [the specified range]. 【0317】 In some embodiments, the pharmaceutical composition has a concentration ranging from about 100 to about 500 ng*h / mL A UC Inf Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of about 125 to about 400 ng*h / mL. Inf In some embodiments, the drug composition has an AUC in the range of about 150 to about 350 ng*h / mL. Inf In some embodiments, the drug composition has an AUC in the range of about 175 to about 300 ng*h / mL. Inf In some embodiments, the drug composition has an AUC in the range of about 200 to about 275 ng*h / mL. Inf In some embodiments, the drug composition has an AUC in the range of about 225 to about 275 ng*h / mL. Inf In some embodiments, the drug composition has an AUC between about 250 and about 275 ng·h / ml. Inf To provide. 【0318】 In some embodiments, the pharmaceutical composition is approximately 225, approximately 226, approximately 227, approximately 228, approximately 229, approximately 230, approximately 231, approximately 232, approximately 233, approximately 234, approximately 235, approximately 236, approximately 237, approximately 238, approximately 239, approximately 240, approximately 241, approximately 242, approximately 243, approximately 245, approximately 246, approximately 247, approximately 248, approximately 249, approximately 250, approximately 251, approximately 252, approximately 253, approximately 254, approximately 255, approximately 256, approximately 257, approximately 258, approximately 259, approximately 260, approximately 261, approximately 262, approximately 263, approximately 265, approximately 266, approximately 267, approximately 268, approximately 269, approximately 270, approximately 271, approximately 272, approximately 273, or approximately 265 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC of approximately 225 ng*h / mL. Inf It provides. In some embodiments, the pharmaceutical composition is about 226 ng*h / mL AUC(Inf) It provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 227 ng*h / mL. Inf Provides a pharmaceutical composition with an AUC of approximately 228 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of approximately 228 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 229 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 230 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 231 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition is approximately 232 ng·h / mL AUC(Inf) In some embodiments, the pharmaceutical composition has an AUC of approximately 233 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 234 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 235 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 236 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 237 ng·h / mL. InfProvides. In some embodiments, the pharmaceutical composition contains approximately 238 ng·h / mL of A UC(Inf) In some embodiments, the pharmaceutical composition has an AUC of approximately 239 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 241 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 242 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 243 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 244 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 245 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 246 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 247 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 248 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 249 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition is approximately 250 ng·h / mL A UC Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 251 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 252 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition is approximately 253 ng·h / mL AUC(Inf) Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 254 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 255 ng·h / mL. InfProvides. In some embodiments, the pharmaceutical composition is approximately 256 ng·h / mL A UC Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 257 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 258 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition contains approximately 259 ng·h / mL of A UC(Inf) Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 260 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 261 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 262 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 263 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 264 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 265 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 266 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of approximately 267 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition is approximately 268 ng·h / mL AUC(Inf) In some embodiments, the pharmaceutical composition has an AUC of approximately 269 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of approximately 270 ng·h / mL. Inf To provide. 【0319】 In some embodiments, the pharmaceutical composition has an AUC in the range of 100 to 500 ng*h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an A concentration in the range of 125 to 400 ng*h / mL. UC(Inf)Provides. In some embodiments, the pharmaceutical composition has an AUC in the range of 150 to 350 ng·h / ml. Inf Provides. In some embodiments, the pharmaceutical composition contains an A concentration in the range of 175 to 300 ng·h / ml. UC(Inf) In some embodiments, the drug composition has an AUC in the range of 200-275 ng*h / mL. Inf The drug composition provides an AUC in the range of 225-275 ng*h / mL. In some embodiments, the drug composition has an AUC in the range of 225-275 ng*h / mL. Inf In some embodiments, the drug composition has an AUC in the range of 250-275 ng*h / mL. Inf To provide. 【0320】 In some embodiments, the pharmaceutical composition is AUC Inf The AUC is 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 265, 266, 267, 268, 269, 270, 271, 272, 273, or 265 ng*h / mL. In some embodiments, the pharmaceutical composition has an AUC Inf It provides 225 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC Inf 226 ng·h / mL を提供する In some embodiments, the pharmaceutical composition has an AUC Inf It provides 227 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 228 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 229 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 229 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 230 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 231 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 231 ng·h / mL. InfProvides a pharmaceutical composition with an AUC of 232 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 232 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 233 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 233 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of 234 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of 235 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 236 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 237 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 237 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 238 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 238 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 239 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 240 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 241 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 241 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 242 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 242 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 243 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 243 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 244 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 244 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 245 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 246 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 246 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 247 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 247 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 248 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 249 ng·h / mL. InfProvides. In some embodiments, the pharmaceutical composition has an AUC of 250 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 251 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 252 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 253 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of 254 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 255 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 256 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 257 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 258 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 258 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 259 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 259 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 260 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 261 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 261 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 262 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 262 ng·h / mL. Inf Provides a pharmaceutical composition with an AUC of 263 ng·h / mL. In some embodiments, the pharmaceutical composition has an AUC of 263 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 264 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 265 ng·h / mL. Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 266 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of 267 ng·h / mL. Inf In some embodiments, the pharmaceutical composition has an AUC of 268 ng·h / mL.Inf Provides. In some embodiments, the pharmaceutical composition has an AUC of 269 ng·h / mL. Inf The pharmaceutical composition provides an AUC of 270 ng*h / mL in some embodiments. Inf To provide. 【0321】 In some examples, AUC Inf This is the geometric mean AUC. Inf That is the case. 【0322】 In some embodiments, AUC Inf The range is the geometric mean AUC. Inf It is within the range of [the specified range]. 【0323】 In some embodiments, the pharmaceutical composition is administered in a CL range of about 2 to about 12 L / hour. z Provides / F. In some embodiments, the pharmaceutical composition provides CL ranging from about 3 to about 12 L / hour. z Provides / F. In some embodiments, the pharmaceutical composition provides CL ranging from about 4 to about 12 L / hour. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 5 to about 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 6 to about 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 7 to about 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 8 to about 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 9 to about 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 10 to about 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 11 to about 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 3 to about 7 L / h. zProvides / F. In some embodiments, the pharmaceutical composition provides CL in the range of about 4 to about 5 L / h. z Provides / F. 【0324】 In some embodiments, the pharmaceutical composition is CL z / F provides approximately 2, approximately 2.5, approximately 3, approximately 3.5, approximately 4, approximately 4.5, approximately 5, approximately 5.5, approximately 6, approximately 6.5, approximately 7, approximately 7.5, approximately 8, approximately 8.5, approximately 9, approximately 9.5, approximately 10, approximately 10.5, approximately 11, approximately 11.5, or approximately 12 L / h. In some embodiments, the drug composition provides approximately 2 L / h of CL z / F を提供 In some embodiments, the pharmaceutical composition is contained in a volume of about 2.5 L / h of CL. z Provides / F. In some embodiments, the pharmaceutical composition provides about 3 L / h of CL. z Provides / F. In some embodiments, the pharmaceutical composition provides about 3.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 4 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 4.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 5.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 6 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 6.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 7 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 7.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 8 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 8.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 9 L / h CL zProvides / F. In some embodiments, the pharmaceutical composition provides about 9.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 10 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 10.5 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 11 L / h CL z Provides / F. In some embodiments, the pharmaceutical composition provides about 11.5 L / h CL z In some embodiments, the pharmaceutical composition provides about 12 L / h of CL. z Provides / F. 【0325】 In some embodiments, the pharmaceutical composition has a CL in the range of 2 to 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition has a CL in the range of 3 to 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition has a CL in the range of 4 to 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition is 5-12 L / hour CL. z Provides / F. In some embodiments, the pharmaceutical composition is 6-12 L / hour CL. z Provides / F. In some embodiments, the pharmaceutical composition provides 7-12 L / hour CL. z Provides / F. In some embodiments, the pharmaceutical composition has a CL in the range of 8 to 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition has a CL in the range of 9 to 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition has a CL in the range of 10 to 12 L / h. z Provides / F. In some embodiments, the pharmaceutical composition provides 11-12 L / hour CL. z Provides / F. In some embodiments, the pharmaceutical composition provides 3 to 7 L / hour CL. z Provides / F. In some embodiments, the pharmaceutical composition provides 4-5 L / hour CL. z Provides / F. 【0326】 In some embodiments, the pharmaceutical composition CL z / F is 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, or 12 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 2.5 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 3.5 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 4.5 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 5.5 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 6.5 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 7.5 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 8.5 L / h. In some embodiments, the pharmaceutical composition is CL z In some embodiments, the pharmaceutical composition is CL z / F is set to 9.5 L / h. In some embodiments, the pharmaceutical composition is CL z Let / F be 10 L / h. In some embodiments, the pharmaceutical composition is CL zLet / F be 10.5 L / h. In some embodiments, the pharmaceutical composition is CL z Let / F be 11 L / h. In some embodiments, the pharmaceutical composition is CL z / F is set to 11.5 L / h. In some embodiments, the pharmaceutical composition is CL z Let / F be 12 L / h. 【0327】 In some embodiments, CL z / F is the geometric mean CL z It is / F. 【0328】 In some embodiments, CL z The range of / F is the geometric mean CL z It is within the range of / F. 【0329】 In some embodiments, the pharmaceutical composition is in a volume ranging from about 100 to about 250 L. z Provides / F. In some embodiments, the pharmaceutical composition is V in the range of about 125 to about 250 L. z Provides / F. In some embodiments, the pharmaceutical composition is V in the range of about 150 to about 250 L. z / F is in the range of approximately 150 to approximately 250 L. In some embodiments, the pharmaceutical composition is V z / F is in the range of approximately 175 to approximately 250 L. In some embodiments, the pharmaceutical composition is V z / F is in the range of approximately 200 to approximately 250 L. In some embodiments, the pharmaceutical composition is V z / F is in the range of approximately 130 to approximately 160 L. In some embodiments, the pharmaceutical composition is V z The / F range is approximately 140 to 150 L. 【0330】 In some embodiments, the pharmaceutical composition is V z / F provides about 100, about 110, about 120, about 130, about 140, about 150, about 160, about 170, about 180, about 190, about 200, about 210, about 220, about 230, about 240 or about 250 L. In some embodiments, the drug composition is provided in about 100 L of Vz Provides V(z) / F. In some embodiments, the drug composition provides about 110 L of V(z) / F. In some embodiments, the drug composition provides about 120 L of V(z) / F. In some embodiments, the drug composition provides about 130 L of V( z) Provides / F. In some embodiments, the drug composition is provided in about 140 L of V z Provides / F. In some embodiments, the drug composition is provided in about 150 L of V( z) Provides V(z) / F. In some embodiments, the drug composition provides about 160 L of V(z) / F. In some embodiments, the drug composition provides about 170 L of V(z) / F. In some embodiments, the drug composition provides about 180 L of V( z) Provides / F. In some embodiments, the drug composition is about 190 L z Let / F be approximately 110 L. In some embodiments, the drug composition is V z Let / F be approximately 120 L. In some embodiments, the drug composition is V z Let / F be approximately 130 L. In some embodiments, the drug composition is V z / F provides approximately 140 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 150 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 160 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 170 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 180 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 190 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 200 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 210 L. In some embodiments, the pharmaceutical composition is V z / F provides approximately 220 L. In some embodiments, the pharmaceutical composition is V z / F is approximately 230L. In some embodiments, the pharmaceutical composition is V z / F is approximately 240L. In some embodiments, the pharmaceutical composition is V z / F is approximately 250L. 【0331】 In some embodiments, the pharmaceutical composition is in a volume of 100 to 250 L. z Provides / F. In some embodiments, the pharmaceutical composition contains V in the range of 125 to 250 L. z Provides / F. In some embodiments, the pharmaceutical composition is V in the range of 150 to 250 L. z / F is provided in the range of 150 to 250 L. In some embodiments, the pharmaceutical composition is V z / F is provided in the range of 175 to 250 L. In some embodiments, the pharmaceutical composition is V z / F is provided in the range of 200-250L. In some embodiments, the pharmaceutical composition is V z / F is in the range of 130 to 160 L. In some embodiments, the drug composition is V z / F is in the range of 140 to 150 L. 【0332】 In some embodiments, the pharmaceutical composition is V z / F is 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240 or 250 L. In some embodiments, the drug composition is V z / F is 100 L. In some embodiments, the pharmaceutical composition is V z / F is 110 L. In some embodiments, the pharmaceutical composition is V z / F is 120 L. In some embodiments, the pharmaceutical composition is V z / F is 130 L. In some embodiments, the pharmaceutical composition is V z / F is 140 L. In some embodiments, the pharmaceutical composition is V z / F is 150 L. In some embodiments, the pharmaceutical composition is V z / F is 160 L. In some embodiments, the pharmaceutical composition is V z / F is 170 L. In some embodiments, the pharmaceutical composition is V z / F is 180 L. In some embodiments, the drug composition is V z / F is 190 L. In some embodiments, the drug composition is V z / F is 200 L. In some embodiments, the drug composition is V z / F is 210 L. In some embodiments, the drug composition is V z / F is 220 L. In some embodiments, the drug composition is V z / F is 230 L. In some embodiments, the drug composition is V z / F is 240 L. In some embodiments, the drug composition is V z / F is 250 L. 【0333】 In some embodiments, V z / F is the geometric mean CL z It is / F. 【0334】 In some embodiments, V z The range of / F is the geometric mean V z It is within the range of / F. 【0335】 In some embodiments, the pharmaceutical composition provides a bioavailability of about 70 to about 100%. In some embodiments, the pharmaceutical composition provides a bioavailability of about 80 to about 100%. In some embodiments, the pharmaceutical composition provides a bioavailability of about 70, about 71, about 72, about 73, about 74, about 75, about 76, about 77, about 78, about 79, about 80, about 81, about 82, about 83, about 84, about 85, about 86, about 87, about 88, about 89, about 90, about 91, about 92, about 93, about 94, about 95, about 96, about 97, about 98, about 99, or about 100%. In some embodiments, the pharmaceutical composition provides a bioavailability of about 85 to about 100%. In some embodiments, the pharmaceutical composition provides a bioavailability of about 90 to about 100%. In some embodiments, the pharmaceutical composition provides a bioavailability of about 95 to about 100%. In some embodiments, the pharmaceutical composition provides approximately 100% bioavailability. 【0336】 In some embodiments, the pharmaceutical composition provides a bioavailability of 70-100%. In some embodiments, the pharmaceutical composition provides a bioavailability of 80-100%. In some embodiments, the pharmaceutical composition provides a bioavailability of 90-100%. In some embodiments, the pharmaceutical composition provides a bioavailability of 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100%. In some embodiments, the pharmaceutical composition provides a bioavailability of 85-100%. In some embodiments, the pharmaceutical composition provides a bioavailability of 90-100%. In some embodiments, the pharmaceutical composition provides a bioavailability of 95-100%. In some embodiments, the pharmaceutical composition provides a bioavailability of 100%. 【0337】 In some embodiments, the pharmaceutical composition contains approximately 8 to approximately 25 ng / mL of C. max AUC of approximately 100 to 450 ng*h / mL last , and 20-200 hours last To provide. 【0338】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 450 ng*h / mL last t in the range of 20 to 200 hours last , and t in the range of approximately 2 to approximately 8 hours max To provide. 【0339】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / ml. max AUC in the range of approximately 100 to 450 ng·h / ml (ラスト)を t in the range of 20 to 200 hours ラスト and V in the range of approximately 100 to approximately 250 liters z Provides / F. 【0340】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 450 ng*h / mL last t in the range of 20 to 200 hours last , and CL in the range of approximately 2 to approximately 12 L / h z Provides / F. 【0341】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 450 ng*h / mL last t in the range of 20 to 200 hours last and provide bioavailability ranging from approximately 70% to 100%. 【0342】 In some embodiments, the pharmaceutical composition contains about 8 to about 25 ng / mL of C. max Approximately 100 to 450 ng*h / mL A UC last , 20-200 hours last Approximately 2 to 8 hours t(max) , and V in the range of approximately 100 to approximately 250 L z / F is in the range of approximately 100 to 250L. 【0343】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 450 ng*h / mL last t in the range of 20 to 200 hours last , in the range of approximately 2 to 8 hours max , and CL in the range of approximately 2 to approximately 12 L / h z The / F range is approximately 2 to 12 L / h. 【0344】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 450 ng*h / mL last t in the range of 20 to 200 hours last , in the range of approximately 2 to 8 hours max V in the range of approximately 100 to 250 L z / F is between approximately 100 and approximately 250L; and CL z The / F should be between approximately 2 and approximately 12 L / h. 【0345】 In some embodiments, the pharmaceutical composition contains approximately 10 to approximately 18 ng / mL of C. max Approximately 150 to 250 ng*h / mL AUC(last) , and 50-70 hours t(last) To provide. 【0346】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 250 ng*h / mL last , in the range of 50-70 hours last , and t in the range of approximately 3 to 5 hours max To provide. 【0347】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 250 ng*h / mL last, in the range of 50-70 hours last , and V in the range of approximately 140 to 160 L z Provides / F. 【0348】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 250 ng*h / mL last , in the range of 50-70 hours last , and CL in the range of approximately 3 to approximately 6 L / h z Provides / F. 【0349】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max , in the range of approximately 150 to approximately 250 ng*h / mL AUC(last) , in the range of 50-70 hours last and provide bioavailability ranging from approximately 70% to 100%. 【0350】 In some embodiments, the pharmaceutical composition contains about 10 to about 18 ng / mL of C. max A, approximately 150-250 ng*h / mL UC(last) 50-70 hours t(last) Approximately 2 to 8 hours t(max) , and V in the range of approximately 140 to 160 L z The / F range is approximately 140 to 160L. 【0351】 In some embodiments, the pharmaceutical composition contains approximately 10 to approximately 18 ng / mL of C. max A, approximately 150-250 ng*h / mL UC(last) , 70-700 hours last Approximately 2 to 8 hours t(max) , and CL of approximately 3 to 5 L / h z The / F is approximately 3 to 5 L / h. 【0352】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 250 ng*h / mLlast , in the range of 50-70 hours last , in the range of approximately 2 to 8 hours max V in the range of approximately 140 to 160 L z / F is between approximately 140 and 160 L; and CL z This provides that / F is between approximately 3 and approximately 5 L / h. 【0353】 In some embodiments, the pharmaceutical composition contains approximately 15 to approximately 18 ng / mL of C. max Approximately 200-250 ng*h / mL AUC(last) , and 50-70 hours t(last) To provide. 【0354】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 250 ng*h / mL last , in the range of 50-70 hours last , and t in the range of approximately 3 to 5 hours max To provide. 【0355】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 250 ng*h / mL last , in the range of 50-70 hours last , and V in the range of approximately 140 to 160 L z Provides / F. 【0356】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 250 ng*h / mL last , in the range of 50-70 hours last , and CL in the range of approximately 3 to approximately 6 L / h z Provides / F. 【0357】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. maxAUC in the range of approximately 200 to 250 ng*h / mL last , in the range of 50-70 hours last and provide bioavailability ranging from approximately 70% to 100%. 【0358】 In some embodiments, the pharmaceutical composition contains approximately 15 to approximately 18 ng / mL of C. max AUC of approximately 200-250 ng*h / mL last 50-70 hours t(last) Approximately 2 to 8 hours t(max) , and V in the range of approximately 140 to 160 L z The / F range is approximately 140 to 160L. 【0359】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 250 ng*h / mL last , t in the range of 70 to 700 hours last , in the range of approximately 2 to 8 hours max , and CL in the range of approximately 3 to approximately 5 L / h z The / F is in the range of approximately 3 to 5 L / h. 【0360】 In some embodiments, the pharmaceutical composition contains approximately 15 to approximately 18 ng / mL of C. max AUC of approximately 200-250 ng*h / mL last 50-70 hours t(last) Approximately 2 to 8 hours max V in the range of approximately 140 to 160 L z / F is between approximately 140 and 160 L; and CL z This provides that / F is between approximately 3 and approximately 5 L / h. 【0361】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max ; and AUC in the range of approximately 100 to approximately 500 ng*h / mL inf To provide. 【0362】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 500 ng*h / mL inf , and t in the range of approximately 2 to approximately 8 hours max To provide. 【0363】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 500 ng*h / mL inf , and V in the range of approximately 100 to approximately 250 L z Provides / F. 【0364】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 500 ng*h / mL inf , and CL in the range of approximately 2 to approximately 12 L / h z Provides / F. 【0365】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 500 ng*h / mL inf and provide bioavailability ranging from approximately 70% to 100%. 【0366】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 500 ng*h / mL inf , in the range of approximately 2 to 8 hours max , and V in the range of approximately 100 to approximately 250 L z Provides / F. 【0367】 In some embodiments, the pharmaceutical composition contains C in the range of about 8 to about 25 ng / mL. max AUC in the range of approximately 100 to 500 ng*h / mL inf , in the range of approximately 2 to 8 hours max , and CL in the range of approximately 2 to approximately 12 L / hz Provides / F. 【0368】 In some embodiments, the pharmaceutical composition contains about 8 to about 25 ng / mL of C. max Approximately 100 to 500 ng*h / mL AUC(inf) Approximately 2 to 8 hours t(max) V z / F is in the range of approximately 100 to approximately 250 L; and CL z The / F should be within the range of approximately 2 to approximately 12 L / h. 【0369】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 300 ng*h / mL inf , and t in the range of 50-70 hours last To provide. 【0370】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 300 ng*h / mL inf , and t in the range of approximately 3 to 5 hours max To provide. 【0371】 In some embodiments, the pharmaceutical composition contains about 10 to about 18 ng / mL of C. max Approximately 150 to 300 ng*h / mL A UC inf , and V z Provides / F. 【0372】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 300 ng*h / mL inf , and CL in the range of approximately 3 to approximately 6 L / h z Provides / F. 【0373】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 300 ng*h / mL inf and provide bioavailability ranging from approximately 70% to 100%. 【0374】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 300 ng*h / mL inf , in the range of approximately 3 to 5 hours max , and V in the range of approximately 140 to 160 L z Provides / F. 【0375】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 300 ng*h / mL inf , in the range of approximately 3 to 5 hours max , and CL in the range of approximately 3 to approximately 6 L / h z Provides / F. 【0376】 In some embodiments, the pharmaceutical composition contains C in the range of about 10 to about 18 ng / mL. max AUC in the range of approximately 150 to 300 ng*h / mL inf , in the range of approximately 3 to 5 hours max V in the range of approximately 140 to 160 L z / F is in the range of approximately 140 to 160 L; and CL z The / F should be in the range of approximately 3 to 6 L / h. 【0377】 In some embodiments, the pharmaceutical composition contains approximately 15 to approximately 18 ng / mL of C. max Approximately 200-300 ng*h / mL AUC(inf) , and 50-70 hours last To provide. 【0378】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL.max AUC in the range of approximately 200 to 300 ng*h / mL inf , and t in the range of approximately 3 to 5 hours max To provide. 【0379】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 300 ng*h / mL inf , and V in the range of approximately 140 to 160 L z Provides / F. 【0380】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 300 ng*h / mL inf , and CL in the range of approximately 3 to approximately 6 L / h z Provides / F. 【0381】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 300 ng*h / mL inf and provide bioavailability ranging from approximately 70% to 100%. 【0382】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 300 ng*h / mL inf , in the range of approximately 3 to 5 hours max , and V in the range of approximately 140 to 160 L z Provides / F. 【0383】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 300 ng*h / mL inf , in the range of approximately 3 to 5 hours max , and CL in the range of approximately 3 to approximately 6 L / h z Provides / F. 【0384】 In some embodiments, the pharmaceutical composition contains C in the range of about 15 to about 18 ng / mL. max AUC in the range of approximately 200 to 300 ng*h / mL inf , in the range of approximately 3 to 5 hours max V in the range of approximately 140 to 160 L z / F is in the range of approximately 140 to 160 L; and CL z The / F should be in the range of approximately 3 to 6 L / h. 【0385】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max AUC of 100-450 ng*h / mL last , and 20-200 hours last To provide. 【0386】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max A 100-450 ng*h / mL UC(last) , 20-200 hours last , and 2-8 hours max To provide. 【0387】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-450 ng*h / mL last t in the range of 20 to 200 hours last , and V in the range of 100-250 L z Provides / F. 【0388】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-450 ng*h / mL last t in the range of 20 to 200 hours last , and CL in the range of 2-12 L / h z Provides / F. 【0389】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-450 ng*h / mL last t in the range of 20 to 200 hours last , and provide bioavailability in the range of 70-100%. 【0390】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max AUC of 100-450 ng*h / mL last , 20-200 hours last , 2-8 hours max , and 100-250 L V z / F is in the range of 100 to 250 L. 【0391】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-450 ng*h / mL last t in the range of 20 to 200 hours last , t in the range of 2 to 8 hours max , and CL in the range of 2-12 L / h z The / F is in the range of 2 to 12 L / h. 【0392】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-450 ng*h / mL last t in the range of 20 to 200 hours last , t in the range of 2 to 8 hours max V in the range of 100-250 L z / F is 100-250 L, CL z The / F is 2-12 L / h. 【0393】 In some embodiments, the pharmaceutical composition is C max The AUC is 10-18 ng / mL. last The concentration is 150-250 ng*h / mL, t last It provides that the time is 50-70 hours. 【0394】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max AUC of 150-250 ng*h / mL last , 50-70 hours last , and 3-5 hours max To provide. 【0395】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max AUC of 150-250 ng*h / mL last , 50-70 hours last , and 140-160 L V z Provides / F. 【0396】 In some embodiments, the pharmaceutical composition contains C in the range of 10 to 18 ng / mL. max AUC in the range of 150-250 ng*h / mL last , in the range of 50-70 hours last , and CL in the range of 3-6 L / h z Provides / F. 【0397】 In some embodiments, the pharmaceutical composition contains C in the range of 10 to 18 ng / mL. max , in the range of 150-250 ng*h / mL AUC(last) , in the range of 50-70 hours last , and provide bioavailability in the range of 70-100%. 【0398】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max , 150-250 ng*h / mL AUC(last) 50-70 hours t(last) , 2-8 hours max , and 140-160 L V z / F is in the range of 140-160 L. 【0399】 In some embodiments, the pharmaceutical composition contains C in the range of 10 to 18 ng / mL. maxAUC in the range of 150-250 ng*h / mL last , t in the range of 70 to 700 hours last , t in the range of 2 to 8 hours max , and CL in the range of 3-5 L / h z The / F is in the range of 3 to 5 L / h. 【0400】 In some embodiments, the pharmaceutical composition is C max 10-18 ng / mL, AUC last 150-250 ng*h / mL, t last 50-70 hours, t max 2-8 hours, V z / F is 140~160 L, CL z The / F is 3-5 L / h. 【0401】 In some embodiments, the pharmaceutical composition is C max The AUC is 15-18 ng / mL. last The concentration is 200-250 ng*h / mL, t last 50-70 hours 提供する . 【0402】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max AUC of 200-250 ng*h / mL last , 50-70 hours last , and 3-5 hours max To provide. 【0403】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max AUC of 200-250 ng*h / mL last , 50-70 hours last , and 140-160 L V z Provides / F. 【0404】 In some embodiments, the pharmaceutical composition contains C in the range of 15-18 ng / mL. max AUC in the range of 200-250 ng*h / mL last , in the range of 50-70 hourslast , and CL in the range of 3-6 L / h z Provides / F. 【0405】 In some embodiments, the pharmaceutical composition contains C in the range of 15-18 ng / mL. max , in the range of 200-250 ng*h / mL AUC(last) , in the range of 50-70 hours last , and provide bioavailability in the range of 70-100%. 【0406】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max AUC of 200-250 ng*h / mL last , 50-70 hours last , 2-8 hours max , and 140-160 L V z / F is in the range of 140-160L. 【0407】 In some embodiments, the pharmaceutical composition contains C in the range of 15-18 ng / mL. max AUC in the range of 200-250 ng*h / mL last , t in the range of 70 to 700 hours last , t in the range of 2 to 8 hours max , and CL in the range of 3-5 L / h z The / F is in the range of 3 to 5 L / h. 【0408】 In some embodiments, the drug composition contains 15-18 ng / mL of C max AUC of 200-250 ng*h / mL last , 50-70 hours last , 2-8 hours max , 140~160 L V z / F is 140~160 L, CL z The / F is 3-5 L / h. 【0409】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max and AUC of 100-500 ng*h / mLinf To provide. 【0410】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-500 ng*h / mL inf , and t in the range of 2 to 8 hours max To provide. 【0411】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max , 100-500 ng*h / mL A UC inf , and 100-250 L V z Provides / F. 【0412】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max AUC of 100-500 ng*h / mL inf , and CL of 2-12 L / h z Provides / F. 【0413】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-500 ng*h / mL inf , and provide bioavailability in the range of 70-100%. 【0414】 In some embodiments, the pharmaceutical composition contains C in the range of 8 to 25 ng / mL. max AUC in the range of 100-500 ng*h / mL inf , t in the range of 2 to 8 hours max , and V in the range of 100-250 L z Provides / F. 【0415】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max AUC of 100-500 ng*h / mL inf , 2-8 hours max , CL 2~12 L / hz Provides / F. 【0416】 In some embodiments, the pharmaceutical composition contains 8-25 ng / mL of C max AUC of 100-500 ng*h / mL inf , 2-8 hours t(max) , 100~250 L V z / F is 100-250 L, CL z The / F is 2-12 L / h. 【0417】 In some embodiments, the pharmaceutical composition contains C in the range of 10 to 18 ng / mL. max AUC in the range of 150-300 ng*h / mL inf , and t in the range of 50-70 hours last To provide. 【0418】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max , 150-300 ng*h / mL AUC(inf) , and 3-5 hours max To provide. 【0419】 In some embodiments, the pharmaceutical composition is C max The AUC is 10-18 ng / mL. inf The concentration is 150-300 ng*h / mL, V z Provides that / F is 140-160 L. 【0420】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max A 150-300 ng*h / mL UC(inf) , and CL of 3-6 L / h z Provides / F. 【0421】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max AUC of 150-300 ng*h / mL inf , and provide a bioavailability of 70-100%. 【0422】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max AUC of 150-300 ng*h / mL inf , 3-5 hours max , and 140-160 L V z Provides / F. 【0423】 In some embodiments, the pharmaceutical composition contains C in the range of 10 to 18 ng / mL. max AUC in the range of 150-300 ng*h / mL inf , t in the range of 3-5 hours max , and CL in the range of 3-6 L / h z Provides / F. 【0424】 In some embodiments, the pharmaceutical composition contains 10-18 ng / mL of C max AUC of 150-300 ng*h / mL inf , 3-5 hours t(max) , 140~160 L V z / F is 140~160L, CL z The / F is 3-6 L / h. 【0425】 In some embodiments, the pharmaceutical composition contains C in the range of 15-18 ng / mL. max AUC in the range of 200-300 ng*h / mL inf , and t in the range of 50-70 hours last To provide. 【0426】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max , 200-300 ng*h / mL AUC(inf) , and 3-5 hours max To provide. 【0427】 In some embodiments, the pharmaceutical composition is C max The AUC is 15-18 ng / mL. inf The concentration is 200-300 ng*h / mL, Vz / F is in the range of 140-160 L. 【0428】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max AUC of 200-300 ng*h / mL inf , and CL of 3-6 L / h z Provides / F. 【0429】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max AUC of 200-300 ng*h / mL inf , and provide a bioavailability of 70-100%. 【0430】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max AUC of 200-300 ng*h / mL inf , 3-5 hours max , and 140-160 L V z Provides / F. 【0431】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max AUC of 200-300 ng*h / mL inf , 3-5 hours max , 3-6 L / h CL z Provides / F. 【0432】 In some embodiments, the pharmaceutical composition contains 15-18 ng / mL of C max , 200-300 ng*h / mL A UC inf , 3-5 hours max , 140~160 L V z The solution provides that / F is within the range of 140 to 160 L, and CLz / F is within the range of 3 to 6 L / h. 【0433】 In some embodiments, the pharmaceutical compositions of the Disclosure exhibit a PK profile substantially similar to that observed after administration to fasted subjects as is observed after administration to fed subjects. In some embodiments, the pharmaceutical compositions of the Disclosure may exhibit a PK profile consistent with that desired for once-daily administration. In some embodiments, the drug composition exhibits a PK profile consistent with that desired when a loading dose is followed by a daily maintenance dose. 【0434】 In some embodiments, the pharmaceutical compositions providing the PK parameters disclosed herein may be administered by various routes, including orally, parenterally, rectally, percutaneously, intradermally, intrathecally, subcutaneously, intravenously, intramuscularly, and intranasally. In some embodiments, the pharmaceutical compositions providing the PK parameters disclosed herein may be provided in any dosage form (e.g., solid (tablets, capsules, etc.), liquid, lipid-based (gelatin capsules, etc.), pre-filled ampoules or syringes of liquid compositions). 【0435】 In some embodiments, the pharmaceutical composition providing the PK parameter comprises compound I or a pharmaceutically acceptable salt thereof, and one or more glycerides, the glycerides comprising monoglycerides in a weight ratio of about 30% to about 100%. 【0436】 How to use Compound I described herein is a positive allosteric modulator of NMDA receptor function and is therefore useful, for example, in the treatment and prevention of certain central nervous system-related conditions in subjects. 【0437】 In one aspect, the present disclosure provides a method for treating a disease, disorder, or condition requiring positive allosteric NMDA receptor modulation in a subject, comprising administering an effective amount of the pharmaceutical composition described in [the document] to the subject. 【0438】 In some embodiments, the Disclosure provides a method for treating a central nervous system-related condition in a subject, which includes administering an effective amount of a pharmaceutical composition disclosed herein to the subject. 【0439】 In some embodiments, the Disclosure provides a method for preventing a disease, disorder, or condition requiring positive allosteric NMDA receptor modulation in a subject. This method involves administering an effective amount of the pharmaceutical composition disclosed herein to the subject. 【0440】 In some embodiments, the pharmaceutical compositions disclosed herein are used to treat diseases, disorders, or conditions that require positive modulation of NMDA receptors in a subject. 【0441】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein, which are used to prevent diseases, disorders, or conditions requiring positive modulation of NMDA receptors in a subject. 【0442】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of pharmaceuticals for treating diseases, disorders, or conditions requiring positive allosteric modulation of NMDA receptors in a subject. 【0443】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of a pharmaceutical product for the prevention of a disease, disorder, or condition requiring positive allosteric NMDA receptor modulation in a subject. 【0444】 In some embodiments, the present disclosure provides a method for treating a disease, disorder, or condition requiring positive allosteric modulation of the NMDA receptor in a subject. In this method, after administration of a pharmaceutical composition to a subject, the pharmaceutical composition provides one or more of the following pharmacokinetic parameters: a) C in the range of about 8 to about 25 ng / mL max b) AUC in the range of approximately 100 to 450 ng*h / mL last c) AUC in the range of approximately 100 to 500 ng*h / mL inf d) t in the range of approximately 2 to 8 hours max ;e)V z / F is between approximately 100 and 250 L; f)CL z / F is between approximately 2 and approximately 12 L / h; or g) bioavailability is between approximately 70 and approximately 100%. 【0445】 In some embodiments, the central nervous system-related disease is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. Parkinson's disease 【0446】 Parkinson's disease affects nerve cells in the brain that produce dopamine. Symptoms include muscle rigidity, tremors, and changes in speech and gait. Parkinsonism is characterized by tremors, bradykinesia, muscle rigidity, and postural instability. While parkinsonism shares symptoms with Parkinson's disease, it is a symptom complex rather than a progressive neurodegenerative disease. 【0447】 In one aspect, this disclosure provides a method for treating or preventing Parkinson's disease in a subject, which comprises administering to the subject a therapeutically effective amount of a pharmaceutical composition described herein. 【0448】 In some embodiments, this disclosure provides a method for treating Parkinson's disease in a subject. This method includes administering a therapeutically effective amount of a pharmaceutical composition described herein to the subject. In some embodiments, this disclosure provides a method for preventing Parkinson's disease in a subject. This method includes administering a therapeutically effective amount of a pharmaceutical composition described herein to the subject. 【0449】 In some embodiments, the Disclosure provides a method for treating cognitive impairment in a subject having Parkinson's disease, which includes administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0450】 In some embodiments, this disclosure provides a method for treating mild cognitive impairment (MCI) associated with Parkinson's disease in a subject. This method involves administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0451】 In some embodiments, the Disclosure provides a method for improving executive function in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0452】 In some embodiments, the Disclosure provides a method for improving working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0453】 In some embodiments, the Disclosure provides a method for improving learning in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0454】 In some embodiments, the Disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0455】 In some embodiments, this disclosure provides a method for improving cognitive function in subjects having Parkinson's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0456】 In some embodiments, the present disclosure provides a method for delaying cognitive decline in subjects with Parkinson's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0457】 In some aspects, this disclosure provides pharmaceutical compositions described herein for use in the treatment or prevention of Parkinson's disease in subjects. In some embodiments, this disclosure provides pharmaceutical compositions described herein for use in the treatment of Parkinson's disease in subjects. In some embodiments, this disclosure provides pharmaceutical compositions described herein for use in the prevention of Parkinson's disease in subjects. 【0458】 In some embodiments, the present disclosure provides pharmaceutical compositions described herein for use in treating cognitive impairment in subjects having Parkinson's disease. 【0459】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of mild cognitive impairment (MCI) associated with Parkinson's disease in subjects. 【0460】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein that are used to improve executive function in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0461】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein that are used to improve working memory in subjects having mild cognitive impairment (MCI) associated with Parkinson's disease. 【0462】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein that are used to improve the learning ability of subjects having mild cognitive impairment (MCI) associated with Parkinson's disease. 【0463】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein that are used to improve learning ability and working memory in subjects having mild cognitive impairment (MCI) associated with Parkinson's disease. 【0464】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein that are used to improve cognitive function in subjects having Parkinson's disease. 【0465】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein that are used to slow cognitive decline in subjects with Parkinson's disease. 【0466】 In some aspects, this disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of a drug for the treatment or prevention of Parkinson's disease in a subject. In some embodiments, this disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of a drug for the treatment of Parkinson's disease in a subject. In some embodiments, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for the prevention of Parkinson's disease in a subject. 【0467】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for treating cognitive impairment in subjects with Parkinson's disease. 【0468】 In some embodiments, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for treating mild cognitive impairment (MCI) associated with Parkinson's disease in subjects. 【0469】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve executive function in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0470】 In some embodiments, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0471】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving learning in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0472】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Parkinson's disease. 【0473】 In some embodiments, the present disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving cognitive function in subjects having Parkinson's disease. 【0474】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for slowing cognitive decline in subjects with Parkinson's disease. 【0475】 In some embodiments, the methods disclosed herein include administering the pharmaceutical compositions described herein in combination with other therapeutic agents used to treat Parkinson's disease. Huntington's disease 【0476】 Huntington's disease is a genetic disorder that depletes nerve cells in the brain. Symptoms include involuntary movements, clumsiness, and balance problems. Huntington's disease can impair walking, speech, and swallowing. 【0477】 In one aspect, this disclosure provides a method for treating or preventing Huntington's disease in a subject, which includes administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0478】 In some embodiments, this disclosure provides a method for treating Huntington's disease in a subject. This method includes administering a therapeutically effective amount of the pharmaceutical composition described herein to the subject. In some embodiments, this disclosure provides a method for preventing Huntington's disease in a subject. This method includes administering a therapeutically effective amount of the pharmaceutical composition described herein to the subject. 【0479】 In some embodiments, the Disclosure provides a method for treating cognitive impairment in a subject having Huntington's disease, which includes administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0480】 In some embodiments, the Disclosure provides a method for treating mild cognitive impairment (MCI) associated with Huntington's disease in a subject. This method involves administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0481】 In some embodiments, the Disclosure provides a method for improving executive function in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0482】 In some embodiments, the present disclosure provides a method for improving working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0483】 In some embodiments, the Disclosure provides a method for improving learning in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0484】 In some embodiments, the present disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0485】 In some embodiments, the present disclosure provides a method for improving cognitive function in a subject having Huntington's disease, which includes administering to the subject a therapeutically effective amount of a pharmaceutical composition described herein. 【0486】 In some aspects, this disclosure provides pharmaceutical compositions described herein for use in the treatment or prevention of Huntington's disease in subjects. In some embodiments, this disclosure provides pharmaceutical compositions described herein for use in the treatment of Huntington's disease in subjects. In some embodiments, this disclosure provides pharmaceutical compositions described herein for use in the prevention of Huntington's disease in subjects. 【0487】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein for use in treating cognitive impairment in subjects having Huntington's disease. 【0488】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of mild cognitive impairment (MCI) associated with Huntington's disease in subjects. 【0489】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein for use in improving executive function in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0490】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein that are used to improve working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0491】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0492】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein that are used to improve learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0493】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein that are used to improve cognitive function in subjects having Huntington's disease. 【0494】 In some embodiments, the present disclosure provides pharmaceutical compositions used to slow cognitive decline in subjects with Huntington's disease. 【0495】 In some embodiments, the Disclosure provides a method for delaying cognitive decline in a subject having Huntington's disease, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0496】 In some aspects, this disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of a pharmaceutical for the treatment or prevention of Huntington's disease in a subject. In some embodiments, this disclosure provides the use of the pharmaceutical compositions disclosed herein in the manufacture of a pharmaceutical for the treatment of Huntington's disease in a subject. In some embodiments, this disclosure provides the use of the pharmaceutical compositions described herein for the manufacture of a pharmaceutical for the prevention of Huntington's disease in a subject. 【0497】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for treating cognitive impairment in subjects with Huntington's disease. 【0498】 In some embodiments, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for the treatment of mild cognitive impairment (MCI) associated with Huntington's disease in subjects. 【0499】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve executive function in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0500】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0501】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve learning in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0502】 In some embodiments, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Huntington's disease. 【0503】 In some embodiments, the present disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving cognitive function in subjects having Huntington's disease. 【0504】 In some embodiments, the present disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for slowing cognitive decline in subjects with Huntington's disease. 【0505】 In some embodiments, the methods disclosed herein involve administering the pharmaceutical compositions described herein in combination with other therapeutic agents used to treat Huntington's disease. Examples of such other therapeutic agents include chorea treatments (e.g., tetrabenazine (TBZ), deuterated tetrabenazine (DBZ)), antipsychotics (e.g., olanzapine, risperidone), antidepressants (e.g., citalopram, fluoxetine, sertraline), and mood stabilizers (e.g., lamotrigine, carbamazepine). Alzheimer's disease 【0506】 Alzheimer's disease (AD) is an age-related neurodegenerative disease. Clinically, it is characterized by general cognitive impairment, particularly memory loss, and behavioral and personality changes. The progression of AD is associated with progressive damage to the function and structure of the hippocampus and neocortex, which are vulnerable brain regions used for memory and cognition. 【0507】 In some respects, this disclosure provides a method for treating or preventing Alzheimer's disease in a subject, which includes administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0508】 In some embodiments, this disclosure provides a method for treating Alzheimer's disease in a subject. This method includes administering a therapeutically effective amount of the pharmaceutical composition described herein to the subject. In some embodiments, this disclosure provides a method for preventing Alzheimer's disease in a subject. This method includes administering a therapeutically effective amount of the pharmaceutical composition described herein to the subject. 【0509】 In some embodiments, the present disclosure provides a method for treating cognitive impairment in a subject having Alzheimer's disease, which includes administering to the subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0510】 In some embodiments, this disclosure provides a method for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in a subject. This method involves administering to a subject a therapeutically effective amount of a pharmaceutical composition described herein. 【0511】 In some embodiments, the Disclosure provides a method for improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0512】 In some embodiments, the present disclosure provides a method for improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0513】 In some embodiments, the Disclosure provides a method for improving learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0514】 In some embodiments, the present disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0515】 In some embodiments, this disclosure provides a method for improving cognitive function in subjects with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0516】 In some embodiments, the present disclosure provides a method for delaying cognitive decline in subjects with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0517】 In some embodiments, the present disclosure provides a method for treating mild cognitive impairment associated with Alzheimer's disease, which involves administering a therapeutically effective amount of the pharmaceutical composition described herein to a subject. 【0518】 In some embodiments, the Disclosure provides a method for improving executive function in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0519】 In some embodiments, the Disclosure provides a method for improving working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0520】 In some embodiments, the present disclosure provides a method for improving learning in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0521】 In some embodiments, the Disclosure provides a method for improving learning ability and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. This method involves administering to a subject a therapeutically effective amount of the pharmaceutical composition described herein. 【0522】 In some respects, this disclosure provides pharmaceutical compositions described herein for use in the treatment or prevention of Alzheimer's disease in subjects. In some embodiments, this disclosure provides pharmaceutical compositions described herein for use in the treatment of Alzheimer's disease in subjects. In some embodiments, this disclosure provides pharmaceutical compositions described herein for use in the prevention of Alzheimer's disease in subjects. 【0523】 In some embodiments, the present disclosure provides pharmaceutical compositions described herein for use in treating cognitive impairment in subjects having Alzheimer's disease. 【0524】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease in subjects. 【0525】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein for use in improving executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0526】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein for use in improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0527】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0528】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0529】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein that are used to improve cognitive function in subjects having Alzheimer's disease. 【0530】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein that are used to slow cognitive decline in subjects having Alzheimer's disease. 【0531】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein for use in the treatment of mild dementia associated with Alzheimer's disease. 【0532】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein that are used to improve executive function in subjects having mild cognitive impairment associated with Alzheimer's disease. 【0533】 In some embodiments, the present disclosure provides pharmaceutical compositions disclosed herein that are used to improve working memory in subjects having mild cognitive impairment associated with Alzheimer's disease. 【0534】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0535】 In some embodiments, the Disclosure provides pharmaceutical compositions disclosed herein for use in improving learning ability and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0536】 In some aspects, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for the treatment or prevention of Alzheimer's disease in a subject. In some embodiments, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for the treatment of Alzheimer's disease in a subject. In some embodiments, this disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of a drug for the prevention of Alzheimer's disease in a subject. 【0537】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for treating cognitive impairment in subjects with Alzheimer's disease. 【0538】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for treating mild cognitive impairment (MCI) associated with Alzheimer's disease in subjects. 【0539】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve executive function in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0540】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0541】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving learning in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0542】 In some embodiments, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve learning ability and working memory in subjects with mild cognitive impairment (MCI) associated with Alzheimer's disease. 【0543】 In some embodiments, the present disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving cognitive function in subjects with Alzheimer's disease. 【0544】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for slowing cognitive decline in subjects with Alzheimer's disease. 【0545】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for the treatment of mild dementia associated with Alzheimer's disease. 【0546】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving executive function in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0547】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0548】 In some embodiments, the disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals for improving learning in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0549】 In some embodiments, the Disclosure provides the use of the pharmaceutical compositions disclosed herein for the manufacture of pharmaceuticals to improve learning ability and working memory in subjects with mild cognitive impairment associated with Alzheimer's disease. 【0550】 In some embodiments, the methods disclosed herein include administering the pharmaceutical compositions described herein in combination with other therapeutic agents used to treat Alzheimer's disease. 【0551】 In some embodiments, the additional therapeutic agent for the treatment of Alzheimer's disease is an anti-amyloid-beta antibody or its antigen-binding fragment, which is an antibody useful in the compositions, kits, and methods of this disclosure. Any anti-amyloid-beta antibody or its antigen-binding fragment described in U.S. Patents 10,842,871, 10,131,708, 9,828,420, and 8,906,367, and U.S. Patent Publication 2015 / 013155267, all of which are incorporated herein by reference, may be used in the pharmaceutical compositions, kits, and methods disclosed herein. 【0552】 More specifically, additional therapeutic agents for the treatment of Alzheimer's disease include anti-amyloid-beta antibodies, their antigen-binding fragments (or portions), antibody light chains, antibody heavy chains, and fragments of these light or heavy chains. The anti-amyloid-beta antibodies and their antigen-binding fragments disclosed herein also include antibodies lacking heavy and / or light chain signal sequences and glycosylated antibodies. The anti-amyloid-beta antibodies and their antigen-binding fragments disclosed herein also include precursor antibodies, non-glycated antibodies, and antibodies in which the heavy and / or light chains contain signal sequences. 【0553】 The antibodies and their antigen-binding fragments described herein can be purified and / or separated using known techniques. “Purified” or “separated” antibodies or portions thereof are at least partially separated from their source (e.g., cell supernatant; mixtures such as antibody mixtures in a library; etc.) and include antibodies obtained by other suitable methods. Separated antibodies include substantially pure (e.g., essentially pure) an...

Claims

[Claim 1] The following drug compositions: a) Compound I: 【Chemistry 10】 (Compound I); its pharmaceutically acceptable salts; and b) One or more glycerides, the glycerides comprising about 30% to about 100% by weight of monoglycerides. [Claim 2] The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition comprises compound I. [Claim 3] A pharmaceutical composition according to any one of claims 1 to 2, wherein the pharmaceutical composition contains a pharmaceutically acceptable salt of compound I. [Claim 4] A pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition contains compound I in an amount of about 0.2% to about 0.4% (by weight). [Claim 5] A pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutical composition contains about 3 mg / g of compound I. [Claim 6] A pharmaceutical composition according to any one of claims 1 to 5, wherein one or more glycerides are selected from the group consisting of glyceryl mono / dicaprylolate, glyceryl mono / dicaprylolate, glyceryl monocaprylate type 1, glyceryl monocaprylate type 1, glyceryl monocaprylolate type 1, glyceryl monolinoleate, and combinations thereof. [Claim 7] In the pharmaceutical composition according to any one of claims 1 to 6, one or more glycerides are selected from the group consisting of glyceryl monocaprylate, glyceryl monolinoleate, and combinations thereof. [Claim 8] A pharmaceutical composition according to any one of claims 1 to 7, wherein the pharmaceutical composition comprises glyceryl monocaprylate. [Claim 9] A pharmaceutical composition according to any one of claims 1 to 7, wherein the pharmaceutical composition contains glyceryl monolinoleate. [Claim 10] A pharmaceutical composition according to any one of claims 1 to 7, wherein the pharmaceutical composition comprises glyceryl monocaprylate and glyceryl monolinoleate. [Claim 11] In the pharmaceutical composition according to any one of claims 1 to 10, the amount of one or more glycerides is approximately 20% by weight to approximately 80% by weight. [Claim 12] A pharmaceutical composition according to any one of claims 7, 9, or 10, wherein the amount of glyceryl monolinoleate is about 20% by weight to about 30% by weight. [Claim 13] A pharmaceutical composition according to any one of claims 1 to 12, further comprising stearoyl polyoxyl 32 glyceride. [Claim 14] In the pharmaceutical composition according to claim 13, the amount of stearoyl polyoxyl 32 glyceride is about 5% by weight to about 20% by weight. [Claim 15] A pharmaceutical composition according to any one of claims 1 to 14, wherein the composition further comprises a surfactant. [Claim 16] In the pharmaceutical composition according to claim 15, the amount of surfactant is about 10% by weight to about 25% by weight. [Claim 17] In the formulation according to any one of claims 15 to 16, the surfactant is vitamin ETPGS. [Claim 18] A pharmaceutical composition according to any one of claims 1 to 17, wherein the composition further comprises an antioxidant. [Claim 19] In the pharmaceutical composition according to claim 18, the amount of antioxidant is about 0.005% (weight / weight) to about 0.02% (weight / weight). [Claim 20] A pharmaceutical composition according to any one of claims 18 to 19, wherein the antioxidant is butylated hydroxyanisole (BHA). [Claim 21] The following drug compositions: a) Contains approximately 0.3% by weight of compound I, b) Approximately 60% by weight of glyceryl monocaprylate, c) Approximately 20% by weight of glyceryl monolinoleate, d) Approximately 20% by weight of Vitamin E TPGS, and e) Approximately 0.01% by weight of butylated hydroxyanisole. [Claim 22] Pharmaceutical composition containing the following ingredients: a) Contains approximately 0.3% by weight of compound I, b) Approximately 50% by weight of glyceryl monocaprylate, c) Approximately 22.5% w / w glyceryl monolinoleate, d) Approximately 20% w / w Vitamin E TPGS, e) Approximately 7.5% w / w stearoyl polyoxyl-32 glyceride, and f) Approximately 0.01% by weight of butylated hydroxyanisole. [Claim 23] A pharmaceutical composition according to any one of claims 1 to 22, wherein the pharmaceutical composition is in the form of an oral dosage. [Claim 24] A pharmaceutical composition according to any one of claims 1 to 23, wherein the pharmaceutical composition is a lipid preparation. [Claim 25] A pharmaceutical composition according to any one of claims 1 to 24, wherein the oral dosage form is a soft gelatin capsule, a hard shell capsule, or an oral liquid. [Claim 26] A pharmaceutical composition according to any one of claims 1 to 25, wherein, after administration of the pharmaceutical composition to a subject, the pharmaceutical composition provides one or more of the following pharmacokinetic parameters: a) C in the range of approximately 8 to approximately 25 ng / mL ｍａｘ ; b) AUC in the range of approximately 100 to approximately 450 ng*h / mL ｌａｓｔ ; c) In the range of approximately 100 to approximately 500 ng·h / mL ＡＵＣ（ｉｎｆ） ; d)t ｍａｘ The duration is in the range of approximately 2 to 8 hours; or e) Approximately 70-100% bioavailability. [Claim 27] Compound I 【Chemistry 11】 (Compound I), or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier, Here, after administration of the pharmaceutical composition to the subject, the pharmaceutical composition provides one or more of the following pharmacokinetic parameters: a) C in the range of approximately 8 to approximately 25 ng / mL ｍａｘ ; b) AUC in the range of approximately 100 to approximately 450 ng*h / mL ｌａｓｔ ; c) A in the range of approximately 100 to approximately 500 ng·h / mL ＵＣ（ｉｎｆ） ; d)t ｍａｘ The duration is in the range of approximately 2 to 8 hours; or e) Approximately 70-100% bioavailability. [Claim 28] The pharmaceutical composition according to claim 27, wherein the pharmaceutical composition has a peak blood concentration value (C ｍａｘ） providing. [Claim 29] A pharmaceutical composition according to any one of claims 27 to 28, wherein the pharmaceutical composition is located between approximately 2 hours and approximately 8 hours. ｍａｘ This provides... [Claim 30] A pharmaceutical composition according to any one of claims 27 to 29, wherein the pharmaceutical composition has an AUC in the range of about 100 to about 450 ng*h / ml. 最終 This provides... [Claim 31] A pharmaceutical composition according to any one of claims 27 to 30, wherein the pharmaceutical composition has an AUC in the range of about 100 to about 500 Ng*h / Ml. インフィ This provides... [Claim 32] A pharmaceutical composition according to any one of claims 27 to 31, wherein the pharmaceutical composition provides about 70% to about 100% bioavailability. [Claim 33] A pharmaceutical composition according to any one of claims 27 to 32, wherein the pharmacokinetic parameters are obtained after a single administration of the pharmaceutical composition. [Claim 34] A pharmaceutical composition according to any one of claims 27 to 32, wherein the pharmacokinetic parameters are obtained after 2 to 60 administrations of the pharmaceutical composition. [Claim 35] A pharmaceutical composition according to any one of claims 27 to 34, wherein the pharmacokinetic parameters are obtained under fasting conditions. [Claim 36] A pharmaceutical composition according to any one of claims 27 to 34, wherein the pharmacokinetic parameters are obtained under postprandial conditions. [Claim 37] A pharmaceutical composition according to any one of claims 27 to 36, wherein the pharmaceutical composition is in the form of an oral dosage. [Claim 38] A method for treating a central nervous system-related disorder in a subject, wherein the central nervous system-related disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition described in any one of claims 1 to 37. [Claim 39] A method for treating cognitive impairment associated with a central nervous system disorder in a subject, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition described in any one of claims 1 to 37. [Claim 40] A method for treating mild cognitive impairment (MCI) associated with a central nervous system disorder in a subject, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition according to any one of claims 1 to 37. [Claim 41] A method for improving executive function in a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition described in any one of claims 1 to 37. [Claim 42] A method for improving working memory in a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition according to any one of claims 1 to 37. [Claim 43] A method for improving learning ability in a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition according to any one of claims 1 to 37. [Claim 44] A method for improving learning and working memory in a subject having mild cognitive impairment (MCI) associated with a central nervous system (CNS) disorder, wherein the CNS disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition according to any one of claims 1 to 37. [Claim 45] A method for improving the cognitive function of a subject having a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease, and the method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition described in any one of claims 1 to 37. [Claim 46] A method for delaying cognitive decline in subjects with central nervous system-related disorders. The aforementioned central nervous system-related diseases are selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. This method comprises administering to the subject a therapeutically effective amount of the pharmaceutical composition described in any one of claims 1 to 37. [Claim 47] A method according to any one of claims 38 to 46, comprising administering compound I to a subject in a total daily dose of about 0.3 mg to about 1.5 mg. [Claim 48] A method according to any one of claims 38 to 46, comprising administering compound I to a subject in a total daily dose of about 1.2 mg. [Claim 49] A method according to any one of claims 38 to 46, comprising administering to a subject about 0.9 mg of compound I as a total daily dose. [Claim 50] A method according to any one of claims 38 to 49, comprising administering to a subject at least one loading dose; and at least one maintenance dose. [Claim 51] In the method according to claim 50, the loading dose is approximately 1.2 mg of compound I per day. [Claim 52] In the method according to any one of claims 50 to 51, the maintenance dose is approximately 0.9 mg of compound I per day. [Claim 53] A pharmaceutical composition according to any one of claims 1 to 37, used for the treatment of a central nervous system-related disorder in a subject, wherein the central nervous system-related disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 54] A pharmaceutical composition according to any one of claims 1 to 37, used for the treatment of cognitive impairment in a subject having a central nervous system-related disease, wherein the central nervous system-related disease is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 55] A pharmaceutical composition according to any one of claims 1 to 37, for use in the treatment of a subject having mild cognitive impairment (MCI) related to a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 56] A pharmaceutical composition according to any one of claims 1 to 37, used to improve executive function in a subject having mild cognitive impairment (MCI) related to a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 57] A pharmaceutical composition according to any one of claims 1 to 37, used to improve working memory in a subject having mild cognitive impairment (MCI) associated with a central nervous system (CNS) disorder, wherein the central nervous system (CNS) disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 58] A pharmaceutical composition according to any one of claims 1 to 37, used to improve the learning ability of a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 59] A pharmaceutical composition according to any one of claims 1 to 37, used to improve the learning ability and working memory of a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 60] A pharmaceutical composition according to any one of claims 1 to 37, used to improve the cognitive function of a subject having a central nervous system-related disease, wherein the central nervous system-related disease is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 61] A pharmaceutical composition according to any one of claims 1 to 37, used to delay the decline of cognitive function in a subject having a central nervous system-related disorder, wherein the central nervous system-related disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 62] A pharmaceutical composition according to any one of claims 1 to 37 is used to manufacture a pharmaceutical for the treatment of a central nervous system-related disorder in a subject, wherein the central nervous system-related disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 63] A pharmaceutical composition according to any one of claims 1 to 37 is used to manufacture a pharmaceutical for the treatment of cognitive impairment in a subject having a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 64] A pharmaceutical composition according to any one of claims 1 to 37 is used to manufacture a pharmaceutical for treating mild cognitive impairment (MCI) associated with central nervous system disorders in a subject, wherein the central nervous system disorders are selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 65] A pharmaceutical composition according to any one of claims 1 to 37 is used to manufacture a pharmaceutical for improving executive function in a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 66] A pharmaceutical composition according to any one of claims 1 to 37 is used to manufacture a pharmaceutical for improving working memory in a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 67] A pharmaceutical composition according to any one of claims 1 to 37 is used to manufacture a pharmaceutical for improving learning ability in a subject having mild cognitive impairment (MCI) associated with a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 68] Use of the pharmaceutical composition according to any one of claims 1 to 37 in the manufacture of a pharmaceutical for improving learning and working memory in subjects having mild cognitive impairment (MCI) associated with central nervous system (CNS) disorders, wherein the central nervous system (CNS) disorders are selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 69] A pharmaceutical composition according to any one of claims 1 to 37 is used in the manufacture of a pharmaceutical product for improving the cognitive function of a subject having a central nervous system disorder, wherein the central nervous system disorder is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 70] A pharmaceutical composition according to any one of claims 1 to 37 is used in the manufacture of a pharmaceutical product for the purpose of delaying cognitive decline in a subject having a central nervous system-related disease, wherein the central nervous system-related disease is selected from the group consisting of Huntington's disease, Parkinson's disease, and Alzheimer's disease. [Claim 71] A dosage plan for administering a therapeutically effective amount of the pharmaceutical composition described in any one of claims 1 to 37 to a subject in need thereof, comprising administering to the subject at least one loading dose and at least one maintenance dose. [Claim 72] In the administration plan according to any one of claims 71, the loading dose is approximately 1.2 mg of compound I per day. [Claim 73] In the administration plan according to any one of claims 71 to 72, the maintenance dose is approximately 0.9 mg of compound I per day. [Claim 74] A method for treating a central nervous system disorder in a subject, wherein the central nervous system disorder is selected from Huntington's disease, Parkinson's disease, and Alzheimer's disease. The treatment method comprises administering a therapeutically effective amount to a subject a pharmaceutical composition comprising compound I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. After administration of the pharmaceutical composition to the subject, the pharmaceutical composition provides one or more of the following pharmacokinetic parameters: a) C in the range of approximately 8 to approximately 25 ng / mL ｍａｘ ; b) AUC in the range of approximately 100 to approximately 450 ng*h / mL ｌａｓｔ ; c) In the range of approximately 100 to approximately 500 ng·h / mL ＡＵＣ（ｉｎｆ） ; d)t ｍａｘ The duration is in the range of approximately 2 to 8 hours; or e) Approximately 70-100% bioavailability.

Images